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   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































R O S A Kartlegging av diabetesomsorgen i Rogaland, Hordaland 
Salten og Oslo/Akershus 
 
SPØRRESKJEMA TIL MEDARBEIDERE OG LEGER 
 
Legekontor:………………………………………………………………………………………………………  
Legekontoret har fellesliste   Ja                  Nei 
 
 Fastlege 1:…………………………………………  Spesialist i allmennmedisin         Ja             Nei 
Antall listepasienter:……………… 
Ant. dager/uke i kurativt arbeid ……………….. 
Kjønn………….             Alder……………………. 
Antall år som allmennlege i Norge:………………………………………. 
Fødeland:………………………………………. 
Utdannelsesland:………………………………………. 
Autorisasjonsår i Norge:………………………………….. 
Antall år bodd i Norge:………………………………………. 
 
 Fastlege 2:…………………………………………  Spesialist i allmennmedisin         Ja             Nei 
Antall listepasienter:……………… 
Ant. dager/uke i kurativt arbeid ……………….. 
Kjønn………….             Alder……………………. 
Antall år som allmennlege i Norge:………………………………………. 
Fødeland:………………………………………. 
Utdannelsesland:………………………………………. 
Autorisasjonsår i Norge:………………………………….. 
Antall år bodd i Norge:………………………………………. 
 
 Fastlege 3:…………………………………………  Spesialist i allmennmedisin         Ja             Nei 
Antall listepasienter:……………… 
Ant. dager/uke i kurativt arbeid ……………….. 
Kjønn………….             Alder……………………. 
Antall år som allmennlege i Norge:………………………………………. 
Fødeland:………………………………………. 
Utdannelsesland:………………………………………. 
Autorisasjonsår i Norge:………………………………….. 




Totalt antall legevikarer som har vært innom legekontoret i 01.10.13-31.12.14:……………….. 
ANDRE ANSATTE ved LEGEKONTORET:  
 
Antall helsesekretærer/medisinske sekretærer:…… Stillingsprosent totalt………………………% 
Antall sykepleiere ……………..…………  Stillingsprosent totalt………………………% 
Antall bioingeniører …….    Stillingsprosent totalt………………………% 
Antall «Annen medisinsk faggruppe»…..  Stillingsprosent totalt………………………% 
 
Diabetessykepleier (ja/ nei):………   Stillingsprosent totalt ……………………….% 
 
Annen medarbeider med spesielt ansvar for diabetespasienter (ja/nei)……. 
Fagruppe/stillingsprosent………………………………..  
 
SETT KRYSS VED RIKTIG SVARALTERNATIV (gjelder for hele legekontoret): 
 
1 REGISTER JA NEI 
 Bruker noen av medarbeiderne Noklus diabetesskjema?   
 Hvis JA, hva fylles ut av medarbeideren? 
Samtykke        Basisdata           Årskontrolldata            Arv           Komplikasjoner 
     
2 INNKALLING   
 Har legekontoret en felles rutine for å kalle inn pasienter til diabetes årskontroll?   
 Er det noe rutine for å kalle inn de pasientene som ikke møter til diabetes årskontroll?   
3 KURS MEDARBEIDERE   
 Hvor mange medarbeidere ved legesenteret har deltatt på kurs i diabetes de siste 3 
årene? Antall:………………… 
  
 Dersom noen har vært på kurs, hvilke kurs: (sett ring rundt det/de aktuelle) 
Diabetes forum, Noklus, egen faggruppe, industri, arbeidsgiver, sykehus, 
annet:………………………………………………………… 
  
4 KOST/LIVSSTILSVEILEDNING   
 Har medarbeidere selvstendige oppgaver knyttet til det å gi 
kostveiledning/livsstilsveiledning til personer med diabetes? 
  
5 EGENMÅLING BLODSUKKER   
 Har medarbeidere selvstendige oppgaver knyttet til det å gi opplæring av pasienter i 
egenmåling av blodsukker? 
  
6 INSULIN   
 Har medarbeidere selvstendige oppgaver knyttet til det å gi opplæring ved oppstart av 
insulin og/eller GLP1 analoger hos pasienter med type 2 diabetes? 
 
  
 I tilfelle JA, hvilke oppgaver har du/dere? 
…………………………………………………………………………………………………… 
  
7 FØTTER   
 Har medarbeidere spesielle oppgaver ved oppfølging av føttene til personer med 
diabetes? 
  
 I tilfelle JA, hvilke oppgaver har du/dere? 
…………………………………………………………………………………………………… 
  
8 ÅRSKONTROLL   
 Har medarbeiderne spesielle oppgaver i tilknytning til årskontrollen?   
 I tilfelle JA, hvilke oppgaver har du/dere? 
…………………………………………………………………………………………………… 
  
9 ANNET   
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ABSTRACT
Objective To assess the status of type 2 diabetes care 
in general practice and changes in the quality of care 
between 2005 and 2014, and to identify areas of diabetes 
care requiring improvement.
Research design and methods Two cross-sectional 
surveys were performed that included patients with type 
2 diabetes in selected areas (n=9464 in 2014, n=5463 
in 2005). Quality of care was assessed based on key 
recommendations in national guidelines. Differences 
in clinical performance between 2005 and 2014 were 
assessed in regression models adjusting for age, sex, 
counties and clustering within general practices.
Results Treatment targets were achieved in a higher 
proportion of patients in 2014 compared with 2005: 
hemoglobin A1c ≤7.0% (≤53 mmol/mol) in 62.8% vs 
54.3%, blood pressure ≤135/80 mm Hg in 44.9% vs 
36.6%, and total cholesterol ≤4.5 mmol/L in 49.9% 
vs 33.5% (all adjusted P≤0.001). Regarding screening 
procedures for microvascular complications, fewer patients 
had recorded an eye examination (61.0% vs 71.5%, 
adjusted P<0.001), whereas more patients underwent 
monofilament test (25.9% vs 18.7%, adjusted P<0.001). 
Testing for albuminuria remained low (30.3%) in 2014. A 
still high percentage were current smokers (22.7%).
Conclusions We found moderate improvements in risk 
factor control for patients with type 2 diabetes in general 
practice during the last decade, which are similar to 
improvements reported in other countries. We report major 
gaps in the performance of recommended screening 
procedures to detect microvascular complications. The 
proportion of daily smokers remains high. We suggest 
incentives to promote further improvements in diabetes 
care in Norway.
INTRODUCTION
Good glycemic control and appropriate 
management of cardiovascular risk factors in 
patients with type 2 diabetes reduce the risk of 
vascular complications and mortality.1–9 The 
Steno-2 trial found an increase in lifespan in 
high-risk patients with type 2 diabetes with 
a combined behavioral and pharmacolog-
ical intervention in a specialist care setting.5 
However, in most countries the majority of 
patients with type 2 diabetes are treated in 
primary care. The initial 5-year follow-up of 
the Anglo-Danish-Dutch Study of Intensive 
Treatment in People with Screen Detected 
Diabetes in Primary Care (ADDITION-Eu-
rope) trial of screening-detected patients 
with type 2 diabetes in general practice found 
improved risk factor levels and a trend toward 
a reduced rate of cardiovascular events, 
microvascular complications and death in 
the multifactorial treatment group compared 
Significance of this study
What is already known about this subject?
 Adequate control of cardiovascular risk factors and 
the early detection of microvascular complications 
may prevent or delay the development of 
complications in type 2 diabetes.
What are the new findings?
 We found moderate improvements in blood 
pressure and lipid control between 2005 and 2014, 
but the performance of screening procedures for 
microvascular complications remained poor.
How might these results change the focus of 
research or clinical practice?
 The results should increase doctors’ awareness of 
the importance of risk factor control and the early 
detection of microvascular complications, and 
may encourage the authorities to create systems 
that can help general practitioners to implement 
guideline recommendations.
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Figure 1 Flow chart of general practices and patients with 
diabetes included in the Rogaland-Oslo-Salten-Akershus-
Hordaland study (ROSA 4) in 2014. GP, general practitioner; 
MODY, maturity onset diabetes of the young.
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with routine care.10 11 A Swedish observational study with 
13 000 patients with type 2 diabetes from general prac-
tice in 2012 reported that fatal and non-fatal cardiovas-
cular disease (CVD) decreased from 23.6% to 6.0% when 
they compared patients achieving a decrease versus an 
increase in hemoglobin A1c (HbA1c), blood pressure 
and lipids.4 It has also been shown that early detection 
of complications by systematic screening and interven-
tion prevents or delays the development of target organ 
disease.12 13
Risk factor control and screening for early complica-
tions can only be closely monitored in countries with 
nationwide and comprehensive diabetes registries such as 
Sweden and Scotland.14 15 Other countries must perform 
cross-sectional surveys to assess status and time trends in 
diabetes care.16–19 In Norway, the quality of type 2 diabetes 
care has been assessed through repeated cross-sec-
tional surveys (Rogaland-Oslo-Salten-Akershus-Horda-
land (ROSA) studies) since 1995. The previous survey, 
ROSA 3, was performed in 2005 and showed substantial 
improvements in glycemic, blood pressure and lipid 
control between 1995 and 2005.20 21
A new assessment of the quality of diabetes care was 
important for several reasons.
First, several new glucose-lowering agents have been 
approved since 2005, and antihyperglycemic drug expen-
diture has increased by approximately 60% in Norway 
and the USA.22 23 Second, during the last decade several 
large studies comparing different treatment targets for 
diabetes have failed to show additional benefit from 
extremely intensive treatment targets.24–26 As a result 
of these studies modern diabetes guidelines emphasize 
the importance of individual treatment targets that may 
influence the overall quality of care.27–29 Finally, Norway 
offers government-funded healthcare services to all 
inhabitants, and these services are expected to provide 
high-quality diabetes care. We therefore designed a large 
cross-sectional survey in 2014, the ROSA 4 study, with the 
objective of assessing the current status of type 2 diabetes 
care in general practice and changes in the quality of 
care between 2005 and 2014, and identifying areas of 
care requiring improvement.
RESEARCH DESIGN AND METHODS
ROSA 4 is a population-based cross-sectional survey 
designed to assess the quality of care of patients with 
type 2 diabetes in general practice in Norway in 2014. We 
included patients with diabetes living in urban and rural 
areas in 5 of 19 counties, covering more than 50% of 
the general population in Norway. General practitioners 
(GPs) in these areas were invited to participate, and 77 
practices (73% of the invited) with 282 GPs (77% of the 
invited) agreed (figure 1). Data were collected from the 
electronic patient records from all the GPs within a prac-
tice by research nurses.
All adults (≥18 years) with a diagnosis of diabetes (T89 
and T90 in the International Classification of Primary 
Care) between 2012 and 2014 were identified using 
customized software that also captured predefined data 
from the electronic patient records. The records were 
examined manually by research nurses to verify elec-
tronically registered data and to collect data not suit-
able for electronic capture. Data capture was performed 
in January 2015–April 2016.
The following variables were registered in the survey: 
patient characteristics (age, sex, ethnicity, diabetes 
duration, height and weight, smoking status); processes 
of care (documentation of HbA1c, blood pressure, 
lipids, creatinine/estimated glomerular filtration rate 
(eGFR), height and weight, smoking habits, eye exam-
ination, albuminuria, monofilament test); medication 
(antihyperglycemic, antihypertensive, antithrombotic 
and lipid-lowering therapy extracted from the GP’s 
electronic prescription files); intermediate outcomes 
(HbA1c, blood pressure, cholesterol, low-density lipo-
protein (LDL), creatinine/eGFR); and vascular compli-
cations (retinopathy, nephropathy (albuminuria, 
eGFR <60 mL/min/1.73 m2), neuropathy (pathological 
10 g monofilament test), foot ulcer, lower limb ampu-
tation, coronary heart disease (angina, myocardial 
infarction, percutaneous coronary intervention/coro-
nary artery bypass surgery), stroke (excluding transient 
ischemic attacks (TIA)), atrial fibrillation, and percu-
taneous transluminal angioplasty/arterial surgery). In 
the present study we included the last registered value 
in 2014 for most variables, except for eye examination, 
creatinine/eGFR and lipids (last registered 2012–2014), 
3BMJ Open Diab Res Care 2017;5:e000459. doi:10.1136/bmjdrc-2017-000459
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and smoking habits (last registered 2010–2014) (online 
supplementary table S1). Medication was extracted from 
the GP’s electronic prescriptions the last 15 months, 
October 1, 2013 to December 31, 2014.
Of the 11 428 patients in the electronic patient records 
with diabetes, 10 248 had type 2 diabetes. Patients who 
did not have their main follow-up in general practice 
(residential patients in nursing homes (n=63), patients 
attending a specialist clinic >1 time/year (n=421), 
patients with a diabetes duration of less than 6 months 
and patients who had died or moved from the practice 
area during 2014 (n=300)), in total n=784 (8%), were 
excluded from the analysis, leaving 9464 patients with 
type 2 diabetes for statistical analysis (figure 1).
The ROSA 3 survey in 2005 used the same inclusion 
and exclusion criteria and methods of data extraction as 
ROSA 4,20 30 and consisted of a sample of 5463 patients 
with type 2 diabetes treated in primary care, from 60 
practices and 205 GPs (online supplementary figure 1). 
The ROSA 4 and ROSA 3 data sets used the same variable 
definition for almost all variables, except that the variable 
stroke excluded TIA in 2014, whereas TIA was included 
in 2005 (online supplementary table S1).
Quality of care was assessed against predefined review 
criteria based on key recommendations in the Norwe-
gian 2009 guidelines31: HbA1c ≤7.0% (53 mmol/mol), 
intervention threshold blood pressure >140/85 mm Hg 
with treatment target ≤135/80 mm Hg, and total choles-
terol ≤4.5 mmol/L. LDL targets were introduced with 
revision of the guidelines in 2009 but were not used in 
the comparison analyses due to missing data in the ROSA 
3 survey.
Statistical analyses
We compared 2014 data with 2005 in regression models 
while controlling for patient age, gender and county of 
GP practice. We present average adjusted predictions 
with CIs adjusted for clustering within GP practices. 
Differences were tested for statistical significance using 
Wald tests. We did not control for diabetes duration 
since new patients may have been diagnosed at an earlier 
stage in the ROSA 4 study due to the introduction of 
HbA1c ≥6.5% (48 mmol/mol) as diagnostic criterion. 
All statistical analyses were performed using STATA/
SE V.14.0 for Windows, with functions logit, mlogit 
and regress, and with margins and test postestimation 
procedures. In consideration of the large sample size 
and correspondingly high statistical power, we applied a 
somewhat strict criterion (P≤0.01) for statistical signifi-
cance. In case of missing data, the percentages of valid 
cases and thus included cases are specified for each 
analysis.
In 2014, data were collected from two more coun-
ties than in 2005. We therefore performed a sensitivity 
analysis comparing data only from the three counties 
included in both ROSA 3 and 4. This analysis gave almost 
identical results for all variables (data not shown).
RESULTS
Study samples
In 2014, 73% of GP practices agreed to participate 
compared with 91% in 2005. We included 9464 (2014) 
and 5463 (2005) patients with type 2 diabetes. Charac-
teristics of the study samples are presented in online 
supplementary table S2. There were more urban resi-
dents (85.2% vs 80.4%) and more men (54.6% vs 50.4%) 
included in 2014 compared with 2005, and the patients 
in 2014 also had a longer duration of diabetes (median 
duration 7 years vs 5 years). The samples were similar 
with regard to age, ethnicity, body mass index (BMI) 
and proportion of current smokers. The proportion 
of smokers was higher among patients <60 years vs ≥60 
years in both 2014 (29.7% vs 19.3%) and 2005 (33.8% vs 
20.4%).
Processes of care
HbA1c, blood pressure and cholesterol were measured 
in most patients (>85%) in both study years; however, 
HbA1c was performed in a lower proportion in 2014 
compared with 2005 (86.4% vs 91.8%, adjusted change 
−4.4 percentage points, P<0.001) (table 1).
Frequencies of measurement of LDL and creatinine/
eGRF were also high in 2014, with 84.4% and 93.2% of 
patients, respectively. Recording of both height/weight 
to estimate BMI was low in both study years (44.6% in 
2014), whereas registration of smoking habits increased 
(79.0% vs 56.0%, adjusted change +24.9 percentage 
points, P<0.001). Procedures related to screening for 
microvascular complications differed between 2014 
and 2005, with fewer patients undergoing eye exam-
ination in 2014 (61.0% vs 71.5%, adjusted change −7.1 
percentage points, P<0.001) and more patients under-
going the monofilament test (25.9% vs 18.7%, adjusted 
change +12.3 percentage points, P<0.001). Testing for 
albuminuria remained low (30.3%) in 2014.
Medication
Hyperglycemia was controlled by diet alone in approxi-
mately one-third of the patients in both surveys (table 2).
There was shift away from insulin in monotherapy 
toward other therapy schemes between 2005 and 
2014 (P<0.001), and the overall frequency of the use 
of insulin also decreased (14.7% vs 22.2%, adjusted 
change −5.6 percentage points, P<0.001). Significantly 
more patients were on combination therapy involving 
more than two agents in 2014 (9.5% vs 1.8%, adjusted 
change +6.9 percentage points). Metformin was the most 
frequently used antihyperglycemic agent in 2014 (57.9%), 
and the use of metformin had increased substantially 
since 2005 (46.3%; adjusted change +9.6 percentage 
points, P<0.001). Use of sulfonylureas, on the other 
hand, was reduced (18.6% vs 30.7%, adjusted change 
−12.4 percentage points, P<0.001). New glucose-lowering 
agents were used by one-fifth of the patients in 2014.
Sixty-six per cent of the patients received antihy-
pertensive medication in both study years; however, 
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Change from 2005 to 2014 
with 95% CI‡
Percentage pointsObserved, with 95% CI† Adjusted‡  Observed Adjusted‡
HbA1c 86.4 (84.9 to 87.9) 86.8 91.8 91.3  −4.4 (−6.7 to −2.1)**
Blood pressure 87.4 (85.8 to 89.0) 88.1 89.7 88.7 −0.5 (−3.2 to 2.2)
Cholesterol 89.0 (86.8 to 91.2) 89.0 89.5 89.6 −0.6 (−3.7 to 2.4)
LDL 84.4 (81.1 to 87.7) 83.8 40.8 41.7  +42.1 (32.9 to 51.2)** 
Creatinine/eGFR 93.2 (91.5 to 95.0) NA
Weight 51.4 (46.7 to 56.1) 51.8 54.2 53.6 −1.8 (−12.7 to 9.1)
BMI 44.6 (40.0 to 49.3) 45.1 36.9 36.3 +8.8 (−1.9 to 19.5)
Smoking habits 79.0 (76.2 to 81.9) 79.6 56.0 54.6  +24.9 (18.3 to 31.5)**
Eye examination 61.0 (57.4 to 64.6) 62.3 71.5 69.4  −7.1 (−11.1 to −3.2)**
Albuminuria 30.3 (25.6 to 34.9) 31.3 37.9 36.1 −4.8 (−13.8 to 4.1)
Monofilament 10 g 25.9 (21.5 to 30.3) 28.1 18.7 15.8  +12.3 (6.6 to 17.9)** 
Number of screening 
procedures for microvascular 
complications§
**
  0 29.2 (25.7 to 32.8) 28.0 21.2 22.8 +5.2 (0.5 to 10.0)
  1 36.3 (34.2 to 41.6) 35.5 41.6 43.0 −7.5 (−11.7 to −3.4)
  2 22.5 (20.0 to 25.0) 23.0 25.7 24.6 −1.6 (−6.5 to 3.2)
  3 12.0 (9.1 to 14.8) 13.4 11.6 9.6 +3.9 (−0.8 to 8.6)
*P≤0.01, **P≤0.001. 
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
 §Screening procedures: eye examination, albuminuria and 10 g monofilament test.
BMI, body mass index; eGFR, estimated glomerular filtration rate; GP, general practitioner; HbA1c, hemoglobin A1c; LDL, low-density 
lipoprotein; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study.
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the use of ACE/AII inhibitors, calcium blockers and 
thiazides all increased (all P≤0.001). The proportion 
of patients on lipid-lowering medication increased 
among patients with coronary heart disease (77.9% 
vs 67.5%, adjusted change +8.8 percentage points, 
P<0.001) as well as in general (54.5% vs 43.7%, adjusted 
change +11.3 percentage points, P<0.001).
Measurements and attained treatment targets
The patients achieved significantly more of the 2009 
national treatment targets in 2014 than in 2005 (P<0.001), 
even though only 16.1% of the patients reached all three 
targets in 2014 (table 3).
HbA1c ≤7.0% (≤53 mmol/mol) was achieved by 
62.8% in 2014 vs 54.3% of the patients in 2005 (adjusted 
change +8.0 percentage points, P<0.001), although the 
mean HbA1c levels declined by only 0.2 percentage 
points (1.6 mmol/mol) (adjusted; P<0.001). Among 
patients on diet only, a high proportion attained the 
HbA1c
 
target in both study years (85.8% in 2014), and in 
2014 an improvement was seen among patients on medi-
cation (53.5% vs 43.7%, adjusted change +7.9 percentage 
points, P=0.001). The proportion with HbA1c >9.0% 
(>75 mmol/mol) was fairly stable (5.6% in 2014).
More patients met blood pressure targets 
(≤135/80 mm Hg on antihypertensive medication and 
≤140/85 mm Hg without medication) in 2014 (50.3% vs 
42.3%, adjusted change +7.2 percentage points, P=0.001), 
and the mean adjusted systolic blood pressure decreased 
by 3.3 mm Hg (P<0.001).
Substantially more patients also achieved the total 
cholesterol target (≤4.5 mmol/L) in 2014 (49.9% 
vs 33.5%, adjusted change +15.4 percentage points, 
P<0.001). Among patients on lipid-lowering medication, 
the proportions reaching target total cholesterol were 
in general higher and also increasing (65.3% vs 49.9%, 
adjusted change +13.7 percentage points, P<0.001). The 
2009 treatment target for LDL was met by 51.9% of all 
patients in 2014; however, among patients with coronary 
heart disease, the proportion with LDL ≤1.8 mmol/L was 
substantially lower: 29.7%.
Vascular complications
The proportion of patients with coronary heart disease 
was relatively stable (22.0% in 2014) (table 4).
There was a marked decrease in the proportion with 
neuropathy and with pathological monofilament test 
results among the relatively few patients registered 
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Table 2 Overview of antihyperglycemic, antihypertensive, lipid-lowering and antithrombotic therapy in patients with type 





Percentages Change from 2005 to 
2014 with 95% CI‡
Percentage points
Observed, with 95% 
CI† Adjusted‡ Observed Adjusted‡
Antihyperglycemic therapy**
  Diet only 31.7 (28.4 to 34.9) 32.5 28.2 27.0 +5.5 (1.0 to 10.1)
  Antihyperglycemic agents except for 
insulin
53.6 (50.8 to 56.5) 52.2 49.6 52.3 −0.1 (−4.2 to 4.1)
  Insulin only 5.4 (4.7 to 6.0) 5.6 12.4 11.6 −6.0 (−7.9 to −4.2)
  Insulin combined with other 
antihyperglycemic agents
9.3 (8.4 to 10.2) 9.7 9.7 9.1 +0.6 (−0.7 to 2.0)
Groups of antihyperglycemic agents
  Metformin 57.9 (54.7 to 61.1) 57.2 46.3 47.6  +9.6 (5.2 to 14.1)**
  Sulfonylurea 18.6 (17.0 to 20.3) 18.5 30.7 31.0  −12.4 (−15.7 to 
−9.1)**
  Insulin 14.7 (13.5 to 15.9) 15.3 22.2 20.9  −5.6 (−8.2 to −3.1)**
  DPP-4 inhibitors 13.9 (12.0 to 15.7) NA
  GLP1 analogs 2.6 (2.1 to 3.1) NA
  SGLT2 inhibitors 3.4 (2.5 to 4.4) NA
Numbers of antihyperglycemic agents, insulin included**
  1 36.2 (34.1 to 38.2) 36.0 43.8 44.4 −8.4 (−11.7 to −5.0)
  2 22.7 (21.3 to 24.0) 22.5 26.2 26.6 −4.2 (−6.6 to −1.7)
  ≥3 9.5 (8.5 to 10.5) 9.0 1.8 2.1 +6.9 (5.9 to 7.9)
Antihypertensive agents
Antihypertensives 65.9 (63.2 to 68.6) 65.9 66.4 66.4 −0.5 (−3.9 to 2.9)
  ACE/AII inhibitors 52.5 (50.1 to 54.8) 52.8 47.4 46.8 +6.0 (2.3 to 9.6)**
  Beta blockers 30.5 (28.6 to 32.3) 30.7 31.2 30.9 −0.3 (−3.0 to 2.5)
  Calcium blockers 25.9 (24.1 to 27.7) 26.6 22.2 21.2  +5.4 (2.9 to 7.9)**
  Thiazides 26.8 (25.1 to 28.6) 27.4 22.0 21.2  +6.2 (3.5 to 9.0)**
Number of antihypertensives**
  1 19.2 (18.2 to 20.2) 19.1 20.0 20.2 −1.1 (−2.9 to 0.8)
  2 20.3 (19.3 to 21.3) 20.2 19.5 19.6 0.6 (−1.2 to 2.4)
  3 16.4 (15.3 to 17.4) 16.5 14.5 14.3 +2.2 (0.6 to 3.8)
  ≥4 10.0 (8.9 to 11.1) 10.4 12.4 11.6 −1.1 (−3.1 to 0.8)
Lipid-lowering medication 54.5 (51.9 to 57.2) 54.7 43.7 43.4  +11.3 (7.1 to 15.5)**
  With coronary heart disease 77.9 (74.3 to 81.5) 77.3 67.5 68.5  +8.8 (3.4 to 14.2)**
Antithrombotic therapy 36.9 (34.7 to 39.2) 37.3 40.3 39.7 −2.5 (−6.0 to 1.1)
Medication was extracted from the GP’s electronic prescriptions. For antithrombotic therapy 0.6% (n=33) were missing in 2005, and for all 
other medication groups data were available in 100% of the cases.
*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
DPP-4, Dipeptidyl peptidase-4; GLP1, Glucagon-like peptide-1; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-
Oslo-Salten-Akershus-Hordaland study; SGLT2, Sodium-glucose co-transporter-2.
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with these variables. Chronic kidney disease as evalu-
ated by eGFR <60 mL/min was present in 17.3% of the 
patients in 2014, whereas 1.7% had eGFR of less than 
30 mL/min.
DISCUSSION
We found clinically important improvements in the 
percentages attaining recommended targets for HbA1c, 
blood pressure and lipids in 2014 vs 2005. However, the 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































recording of screening procedures for microvascular 
complications remained alarmingly poor. Furthermore, 
the proportion of current smokers was disturbingly 
high.
Study samples
We consider our findings to be representative for patients 
with type 2 diabetes treated by GPs in Norway. In both the 
ROSA 4 and ROSA 3 surveys, data were collected from 
routine clinical practice, with all GPs in a practice partic-
ipating. Furthermore, patients in the 2014 survey were 
similar to the type 2 diabetes population in the compre-
hensive Swedish and Scottish diabetes registries in 2014 
and with other recently published surveys from Europe 
and the USA with respect to age, gender, diabetes dura-
tion and BMI.9 14 15 18 32–35
Processes of care
Recordings of HbA1c, blood pressure, lipids and 
smoking status in 2014 were acceptable and comparable 
to other surveys, while recording of weight/BMI was 
low.14 15 36 Screening for microvascular complications was 
poor and inferior to that found in the diabetes registries 
from Sweden and Scotland, in the UK National Diabetes 
Audit and in cross-sectional studies in the USA.14–16 36 
When comparing the results from ROSA 4 with Sweden, 
Scotland, UK and the USA, the proportions with annual 
checks for albuminuria were 30% vs 73%–75%, neurop-
athy 26% vs 71%–94%, and eye examination 61% vs 
70%–90%. Surprisingly, the percentage of patients with 
a recorded ophthalmological examination was lower 
in 2014 than in 2005. The differences between Norway 
and Sweden may be due to the use of reminders on the 
fill-in forms used by practices to report to the registry and 
the availability of diabetes specialist nurses in GP prac-
tices in Sweden. In addition, national initiatives in the 
UK to improve care for people with diabetes may have 
led to increasing screening rates, that is, the National 
Service Framework for Diabetes.37 In pediatric diabetes 
care in Norway, it has been shown that establishment of 
a nationwide system for benchmarking of quality indica-
tors resulted in significant improvements in risk factor 
control and screening assessments.38
In the general population in Norway, the percentage 
of current smokers decreased from 24% in 2004 to 
13% in 2014.39 In contrast the prevalence of current 
smokers in ROSA 4 remained high (22.0%) and similar 
to reports from the American National Health and 
Nutrition Examination Survey (NHANES), where 
the prevalence remained unchanged at 22% between 
1999–2002 and 2007–2010.16 Corresponding percent-
ages in Sweden and Scotland in 2014 were 15% and 
18%.14 15 A Swedish study found an excess mortality in 
patients with type 2 diabetes younger than 55 years, 
and 38% of these were current smokers.9 Motivating 
patients with diabetes to stop smoking should be an 
important priority for GPs.
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Medication, measurements and attained treatment targets
In accordance with national guidelines, the percentage 
of patients using metformin increased. The use of sulfon-
ylureas decreased substantially (−12 percentage points). 
The same trends were seen in a recent publication from 
the USA.35
Risk factor control has improved during the last 
decade. The increase in achievement of HbA1c targets 
was similar to the observations between the periods 
1999–2002 and 2007–2010 in NHANES (+8 percentage 
points).16 Compared with recent cross-sectional studies 
or annual reports from diabetes registries of type 2 
diabetes in general practice worldwide, the proportion 
of patients achieving HbA1c <7.0% (<53 mmol/mol) in 
ROSA 4 was 57% vs 47%–52%.15 16 18 19 This confirms that 
glycemic control in Norwegian general practice is similar 
to other countries. We only found a slight improvement in 
mean HbA1c that was similar to findings in reports from 
the Swedish Diabetes Registry and NHANES.14 16 The 
decrease in mean HbA1c was only 0.2 percentage points 
(1.6 mmol/mol) despite the fact that antihyperglycemic 
drug expenditures increased by 60%. The relatively small 
decline in mean HbA1c seen during the last decade may 
be due to the reduction of the use of insulin. It is possible 
that the GPs postpone insulin treatment, and start with 
the new expensive antihyperglycemic agents, which have 
less glucose-lowering effect than insulin. During recent 
years guidelines have emphasized the need for individual 
glycemic treatment targets for patients with long diabetes 
duration and comorbidities.27–29 These targets are often 
less intensive than previously strict recommendations 
and may also explain the clinically insignificant change 
in mean HbA1c. Finally, mean HbA1c is now at such a 
low level that lower mean values are difficult to achieve in 
large study populations.
There was no significant decrease in BMI in 2014 
compared with 2005 despite the introduction of 
weight-neutral and weight-reducing therapies. However, 
the proportion of patients on such therapies was rela-
tively low in 2014 (Dipeptidyl peptidase 4 (DPP4) inhib-
itors 13.9%, Sodium-glucose co-transporter-2 (SGLT2) 
inhibitors, 3.4%, Glucagon-like peptide-1 (GLP1) analogs 
2.6%).
The increased use of ACE/II inhibitors, calcium 
blockers and thiazides probably explains the improved 
blood pressure control. However, there is still a high 
proportion of untreated patients above intervention 
threshold and treated patients above blood pressure 
targets. In our present study 38.5% achieved a blood 
pressure ≤130/80 mm Hg (regardless of medication) in 
2014. Findings from other countries span from 33.8% 
(Scotland) and 41.6% (Swedish Diabetes Registry), to 
51.3% (NHANES).15 16 19
The improved control of dyslipidemia might be influ-
enced by the introduction of LDL targets in national 
guidelines in 2009.31 The proportion of patients on 
lipid-lowering therapy with cholesterol <4.5 mmol/L was 
similar in ROSA 4 and the Swedish Diabetes Registry 
(62.0% vs 59.0%), while the Swedish had a higher propor-
tion with LDL <2.5 mmol/L (42.3% vs 52.6%). The use 
of statins in ROSA 4 was inferior to Sweden (54.5% vs 
63.7%). Only 28.5% of patients with a history of CVD 
attained LDL target ≤1.8 mmol/L, similar to results from 
NHANES (27.5%).16 This indicates that more patients 
with diabetes should start lipid-lowering therapy in 
Norway and that GPs should maintain efforts to achieve 
the strict LDL target in high-risk persons with CVD.
Vascular complications
There was no significant change in the prevalence of 
coronary heart disease during the last decade in our 
study populations. This is similar to the findings in 
two recent cross-sectional surveys from the USA.33 35 
The prevalence of microvascular complications in our 
study is subject to uncertainty due to poor recording 
of screening among GPs in both surveys (~60% eye 
examination, ~30% albuminuria test and ~25% mono-
filament test in 2014). We found no significant change 
in retinopathy between ROSA 4 and ROSA 3, but 
the 12.3% prevalence of patients with retinopathy in 
2014 is probably underestimated due to inconsistent 
reporting. The Swedish Adult Diabetes Register 
reports a prevalence of retinopathy of 29.6% in their 
annual 2014 report. Their findings are probably more 
representative of retinopathy among patients with type 
2 diabetes in general practice in Scandinavia.14 Fewer 
persons had neuropathy in ROSA 4 compared with 
ROSA 3, while more patients had a recorded mono-
filament test. The finding may be explained by selec-
tion bias if GPs in 2005 used monofilament test more 
frequently in patients suspected of having neuropathy. 
The prevalence of neuropathy in 2014 (18.8%) is in 
agreement with reports from the Swedish National 
Diabetes Register 2014 (21%), and both countries 
have ~2.7% with a history of foot ulcer. ROSA 4 and 
Scotland report similar percentages of lower limb 
amputation (0.6% and 0.7%, respectively). ROSA 4 
and Scotland have the same proportion of patients 
with end-stage renal failure (0.6%).
Strengths and weaknesses
This study is one of the largest representative cross-sec-
tional studies of type 2 diabetes in general practice 
performed in recent years, originating from a high-in-
come country with an apparently well-organized health-
care system. Our study has some limitations. Screening 
procedures for microvascular complications are based 
on recorded data in the case notes. If GPs fail to record 
performed procedures, our results will overestimate the 
quality gaps. The level of albuminuria is not reported 
due to different measurement methods/units between 
GP practices, and frequent missing data. Finally, we 
excluded patients with main-follow up in specialist 
healthcare who probably had worse glycemic control; 
however, the absolute numbers were small and unlikely 
to influence the results (4.4% in 2014 vs 5.0% in 2005).
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In summary, we found moderate improvements 
in blood pressure and lipid control during the last 
decade, which are similar to improvements reported 
from other countries. Improvements during the last 
decade are less striking than improvements reported in 
the previous decade. We demonstrated that there are 
still major gaps in the performance of recommended 
screening procedures to detect microvascular compli-
cations. Clinical performance in this area was consid-
erably worse than other comparable countries. We 
also found a disturbingly high proportion of current 
smokers diverging from trends seen in the general 
Norwegian population. There is still considerable 
room for improvements of many aspects of diabetes 
care in general practice. Screening for microvascular 
complications must be improved. Risk factor control, 
especially the treatment of dyslipidemia, and the 
promotion of smoking cessation require attention. We 
suggest compulsory reporting to a national diabetes 
register and feedback to GPs as a means of continu-
ally evaluating diabetes control and promoting further 
improvements in diabetes care in Norway. A national 
screening program for diabetes retinopathy should also 
be considered.
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660 patients with type 1 diabetes 
were excluded 
769 patients with type 2 diabetes 
were excluded due to not having 
main follow up by a GP 
Dead/moved/newly diagnosed 
(n=355), nursing home (n=143), 
main follow-up by specialist 
(n=271) 
5463 patients with type 2 
diabetes were included 
 
66 practices were invited  
6232 patients with type 2 
diabetes  
 
60 practices with 205 GPs  
and their 6892 patients with 
diabetes  
6 practices did not respond or 
did not want to participate 
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Supplemental Table S1 
Variables extraction in the ROSA 4 survey (2014) and ROSA 3 survey (2005) 
 
 Variables ROSA 4 (2014)  ROSA 3 (2005) 
Characteristics   
 Diabetes duration 2014 minus year of diagnosis 2005 minus year of diagnosis 
 Ethnicity Caucasians or others Caucasians or others 
 Height If ever registered If ever registered 
 Weight 15 months 12 months 
 BMI 15 months 12 months 
 Current smokers No; if ever registered as non-
smoker.  
Yes; if registered as current 
smoker the last 5 years and not 
changed smoking status 
No; if ever registered as non-
smoker.  
Yes; if registered as current 
smoker the last 3 years  




 Retinopathy If ever registered If ever registered 




 Coronary heart disease If ever registered If ever registered 
 Stroke If ever registered apoplexia 
cerebri 
If ever registered apoplexia 
cerebri or TIA 
 Diabetic foot ulcer If ever registered If ever registered 
Processes of care   
 HbA1c 12 months 12 months 
 Blood pressure 15 months 12 months 
 Lipids 36 months 36 months 
 Creatinine/eGFR 36 months 
 
 Documentation of 
smoking status 
Non-smokers if ever registered. 
Smokers 5 years 
Non-smokers if ever registered. 
Smokers 36 months. 
Microvascular screening   
 Monofilament test 15 months 12 months 
 Albuminuria 12 months 12 months 
 Eye examination Eye examination 24 months, 
referral eye specialist 30 
months 
Eye examination or referral to eye 
specialist 24 months 
Medication   
 Digitally extracted prescriptions 
15 months 
Digitally extracted prescriptions 
 
Retinopathy: Non-proliferative and proliferative retinopathy regardless of treatment, macula oedema excluded.  
Reduced foot sensibility: Pathological monofilament test and/or any form of vibration test 
Monofilament test: 10-g monofilament, pathological if absence of sensation of  ≥1 of 8 touches 
Coronary heart disease: Acute myocardial infarction, angina, percutaneous coronary intervention/coronary artery 
bypass surgery. TIA: Transient ischemic attacks  
2014: 12 months (Jan. 1st to Dec. 31st 2014), 15 months (Oct. 1st 2013 to Dec. 31st 2014), 24 months (Jan. 1st 
2004 to Dec. 31st 2005), 30 months (July 1st 2012 to Dec. 31st 2014).  
2005: 12 months (Jan. 1st to Dec. 31st 2005), 24 months (Jan 1st 2004 to Dec. 31st 2005), 36 months (Jan. 1st 2003 










Supplemental Table S2 
Characteristics of type 2 diabetes patients in general practice in Norway in 2014 (ROSA 4) compared with 2005 
(ROSA 3) 
 






Male (%) 100/100 54.6 50.4  
Age (years) 100/100 66.0 (48.0 to 82.0) 65.9 (48.0 to 83.0) 
Caucasian (%) 99/100 86.3  89.7 
Current smokers (%) 79/56 22.7  25.2  
Urban (%) 100/100 85.2  80.4  
Diabetes duration (years) 94/94 7.0 (1.0 to 18.0) 5.0 (1.0 to 14.0) 
BMI (kg/m2)  45/37 29.2 (23.6 to 37.7) 29.0 (23.3 to 37.2) 
Bariatric surgery (%) 100/ NA 1.5  NA 
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Abstract
Aims To assess population, general practitioner (GP) and practice characteristics associated with the performance of
microvascular screening procedures and to propose strategies to improve Type 2 diabetes care.
Methods A cross-sectional survey in Norway (281 GPs from 77 practices) identified 8246 people with a Type 2
diabetes duration of 1 year or more. We used multilevel regression models with either the recording of at least two of
three recommended screening procedures (albuminuria, monofilament, eye examination) or each procedure separately as
dependent variable (yes/no), and characteristics related to the person with diabetes, GP or practice as independent
variables.
Results The performance of recommended screening procedures was recorded in the following percentages:
albuminuria 31.5%, monofilament 27.5% and eye examination 60.0%. There was substantial heterogeneity between
practices, and between GPs within practices for all procedures. Compared with people aged 60–69 years, those aged
< 50 years were less likely to have an albuminuria test performed [odds ratio (OR) 0.75, 95% CI 0.61 to 0.93] and
eye examination (OR 0.79, 95% CI 0.66 to 0.95). People with macrovascular disease had fewer screening procedures
recorded (OR 0.68, 95% CI 0.59 to 0.78). Use of an electronic diabetes form was associated with improved
screening (OR 2.65, 95% CI 1.86 to 3.78). GPs with high workload recorded fewer procedures (OR 0.59, 95% CI 0.39
to 0.90).
Conclusions Performance of screening procedures was suboptimal overall, and in people who should be prioritized.
Performance varied substantially between GPs and practices. The use of a structured diabetes form should be mandatory.
Diabet. Med. 00: 1–13 (2018)
Introduction
Diabetes guidelines worldwide recommend regular screening
to detect microvascular complications, because early detec-
tion and intervention is important to slow the progression of
target organ disease [1–3]. Microvascular disease has
significant associations with cardiovascular disease, espe-
cially for albuminuria [4–6]. An impaired monofilament test
will identify those at moderate risk of foot ulceration, and
early eye examination is important to prevent severe stages of
retinopathy [7,8]. A urine albumin test and a 10-g monofil-
ament test should be performed at the time of diagnosis of
Correspondence to: !Asne Bakke. E-mail: asne.bakke@sus.no
*Joint senior authors.
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Type 2 diabetes and thereafter annually [1,2]. Eye examina-
tion should also be performed at diagnosis and repeated at
least biannually [1,2].
Recently, we assessed the quality of care for ~ 9500 people
with Type 2 diabetes in general practice in Norway in 2014
using data from the Rogaland–Oslo–Salten–Akershus–
Hordaland study (ROSA 4 study) [9]. Measurements of
HbA1c, blood pressure, lipids and eGFR were available for
! 90% of people assessed, and the achievement of treatment
targets were comparable with reports from other countries.
However, we found major gaps in screening procedures to
detect microvascular complications. Fewer than a third had
recorded a test for albuminuria, only one in four had
recorded a monofilament test and ~ 60% had a biannual eye
examination recorded. The reasons for this poor perfor-
mance are not known. The results are substantially lower
than reports from the National Diabetes Audit (UK), and the
Scottish and Swedish diabetes registries [10–12]. Compared
with these countries, general practitioners (GPs) in Norway
have fewer economic incentives that promote microvascular
screening. Furthermore, reporting to the consent-based
Norwegian Diabetes Registry is not compulsory and only a
minority of GPs send patient data to the registry.
Studies identifying healthcare factors that predict the
performance of screening for microvascular complications
in diabetes care are scarce. Such studies usually assess quality
improvement strategies, the introduction of incentives, feed-
back to GPs or involvement of ancillary staff [13–16]. Our
objectives were to identify person, GP and practice charac-
teristics that are associated with the performance of screen-
ing procedures for microvascular complications in routine
clinical practice, and if possible propose strategies that may
improve Type 2 diabetes care.
Participants and methods
The ROSA 4 study is a large population-based cross-
sectional study of diabetes care in Norwegian general
practice that collected data from 2014 [9]. We invited GP
practices located in five of Norway’s 19 counties including
urban and rural areas. We included some urban districts with
low socio-economic status and a high proportion of ethnic
minorities. In total, 282 GPs (77% of those invited) and 77
practices (73% of those invited) participated in the study. All
GPs within a practice were included.
Sample size
We collected information from the electronic health records
(EHR) of all adults with Type 2 diabetes (n = 10 248)
registered on the participating GPs’ lists [9]. We included
people with Type 2 diabetes aged 18 years or more who had
their main follow-up in general practice and a diabetes
duration of 1 year or more (n = 8 951) (Fig. 1). For
regression analyses, we excluded 705 people with Type 2
diabetes due to missing data and one GP responsible for only
one person with diabetes, leaving 8246 people with diabetes
and 281 GPs in 77 practices for analysis.
Data were captured from electronic records and manually
verified by research nurses from January 2015 to April 2016.
Ethnicity and education were obtained by linkage to Statistics
Norway. A questionnaire was used to gather information
related to the GPs and the practices. The response rate after
reminders reached 99%completed questionnaires forGPs and
100% for GP practices. The ROSA 4 survey was approved by
the Regional Ethical Committee in Norway (2014/1374 REK
Vest) and conforms to the Declaration of Helsinki.
The primary outcome was the recording of at least two of
the three recommended procedures to detect microvascular
complications: albuminuria and monofilament within the last
15 months (1 October 2013 to 31 December 2014) and an
eye examination within the last 30 months (1 July 2012 to 31
December 2014). Eye examinations were performed by
ophthalmologists, but GPs acted as gatekeepers referring
people with diabetes to the ophthalmologists. We examined
associations between the primary outcome and population,
GP and practice characteristics from the electronic records
and the two questionnaires. In addition, we examined
associations between these characteristics and each proce-
dure separately.
Person variables
For people with diabetes we collected data on gender, age,
diabetes duration, ethnicity (Western Europe/North America
vs. others), registered current smoker (yes/no), education
(primary school, high school/apprenticeship certification,
What’s new?
• We found major gaps in microvascular complication
screening in Norwegian general practice among people
with Type 2 diabetes.
• Screening procedures for microvascular complications
were associated with population, general practitioner
(GP) and practice characteristics.
• People with short diabetes duration and with no oral
anti-hyperglycaemic therapy were rarely screened for
complications.
• Younger people (aged < 50 years), and people with
macrovascular disease were less likely to have screening
procedures performed.
• GP use of a structured diabetes form was associated
with higher recordings of microvascular screening
procedures.
• Practices with routines for annual diabetes review were
more likely to record screening procedures.
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university), bariatric surgery, macrovascular complications
(angina, myocardial infarction, stroke or percutaneous
coronary intervention/coronary artery bypass surgery), eGFR
calculated by the Chronic Kidney Disease Epidemiology
collaboration (CKD-EPI) equation [17], HbA1c, LDL-choles-
terol, BP andmedication (anti-hyperglycaemic, anti-hypertensive
and lipid-lowering therapy). We used the last registered value
from the past 3 years for eGFRandLDL-cholesterol, and from
the last 15 months for HbA1c and BP, and dichotomized as
follows: eGFR < 45 ml min#1 1.73m#2, HbA1c ≥ 64 mmol/
mol (≥ 8.0%), LDL > 3.5 mmol/l and BP > 140/85 mmHg. In
the multivariable analyses, missing values for these variables
were defined as ‘not registered with risk factors’. We did not
include BMI in the main analyses because nearly 50% had no
weight recorded the last 15 months.
GP variables
GP variables were gender, age, specialist in general practice,
days in clinical practice (> 3 vs. ≤ 3 days/week), country of
birth (Norway vs. other), country of graduation as medical
doctor (Norway vs. other), ≤ 5 years practising as a GP in
Norway, number of people with Type 2 diabetes on the GPs’
list, total number of people on GPs’ list per day worked each
week, and use of a structured, electronic form (Noklus
diabetes form) in the follow-up. The GP was defined as a user
of the form if he/she had used the form in 10 ormore people or
in > 50% of the people with Type 2 diabetes on their list. We
lacked information on number of years practising in Norway
for 11 GPs (3.9%). The missing data were imputed based on
the year of Norwegian authorization (known for all GPs).
Practice variables
Practice variables were county, urban location (municipali-
ties with > 80% of the population living in densely populated
areas according to data from Statistics Norway), practice size
(number of GPs per office), total number of people on the list
per full-time employed nurse/medical secretary, ancillary
staff with diabetes competency (either a specialized diabetes
nurse or staff attending a diabetes course within the past
3 years), ancillary staff with responsibility for at least one of
FIGURE 1 Flow chart depicting the exclusion process for people with diabetes in the ROSA 4 study to fit criteria for the regression analysis of the
present study. ROSA 4 (Rogaland-Oslo-Salten-Akershus-Hordaland study in 2014); GP, general practitioner; LADA, latent autoimmune diabetes of
the adult; MODY, maturity onset diabetes of the young.
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the three microvascular procedures, and the use of a
reminder system for the annual diabetes care review.
Statistical analyses
Descriptive statistics are presented as medians, 10th and 90th
percentiles for continuous variables, otherwise as percent-
ages. A Venn diagram is presented for the main outcomes. We
used multilevel logistic regression models with the recording
of at least two of the three procedures to detect microvascular
complications as the dependent variable (yes/no) and char-
acteristics related to people with diabetes (level 1), GPs (level
2) and the GP practices (level 3) as independent variables. In
addition, we performed analyses with each procedure sepa-
rately. We report ORs with 95% CIs and with corresponding
P-values from v2 tests. Continuous independent variables
were assessed for linearity of effects, and analysed on a
categorized scale if this assumption was not met. Variance
inflation factors were estimated to check for multicollinear-
ity. Presented results are from univariable analyses and from
multivariable analysis with all independent variables on all
levels included in the model. All models were fitted using
adaptive Gaussian quadrature with seven integration points.
For level 2 and 3 variables, a P-value ≤ 0.05 was considered
to be statistically significant; however, due to the large sample
size, we used P ≤ 0.01 for level 1 (people with diabetes)
variables. The partition of variance in the three levels was
estimated by intra-cluster correlation coefficients, and we
also estimated the proportion change in cluster variance by
introduction of explanatory variables [18].
The software program STATA version 15.1 was used with
functions xtmelogit and estat icc. The Venn diagram was
constructed using Python version 3.7 with packageMatplotlib.
Results
We included 8246 people with Type 2 diabetes attending
281 GPs in 77 practices for analyses. An overview of
recorded procedures is shown in Table 1 and Fig. 2. Thirty-
five per cent of people with diabetes had two or more
screening procedures performed, and approximately one-
quarter had none of the recommended procedures per-
formed. Individual, GP and practice characteristics are
summarized in Tables 2 and 3, whereas associations
between various characteristics and screening procedures
are presented in Tables 4a, 4b, 5a and 5b. Partitions of
variation in performance of screening procedures between
practices and between people with diabetes, GPs, and
practices are given for various models in Table S1.
Characteristics of people with Type 2 diabetes associated
with microvascular screening procedures
People aged < 50 years had procedures recorded less often
than those aged 60–69 years. People aged ≥ 80 years had
procedures performed less frequently with the exception of
eye examination. Longer diabetes duration was associated
with increased recording of microvascular screening. The
odds for having recorded procedures increased by 14% per 5
years of diabetes duration (OR 1.14), and even more for eye
examination (OR 1.26). People from ethnic minorities and
people with a lower level of education were less likely to have
two screening procedures performed.
People with macrovascular complications had reduced
odds of recorded screening procedures (OR 0.68), as had
registered current smokers (OR 0.68).
Users of anti-hyperglycaemic agents had two times the
odds of having at least two screening procedures
recorded compared with people on diet only. Those on
anti-hypertensive or lipid-lowering therapies also
achieved the primary outcome more often. Blood pres-
sure above intervention thresholds (> 140/85 mmHg) was
associated with having microvascular screening proce-
dures recorded.
GP characteristics associated with microvascular screening
procedures
GPs using a structured electronic diabetes form in the follow-
up of people with diabetes had an OR of 2.65 for performing
at least two microvascular screening procedures compared
with non-users, and an OR of 4.51 for performing a
monofilament test. GPs who were specialists in general
practice had higher odds of recording two or more microvas-
cular procedures (OR 1.50), especially for the albuminuria
test (OR 1.73). GP workload seemed to affect the recording
of procedures. If GPs had a total list size of 250–350 people
per clinical day worked each week, they had significantly
lower odds of recording screening procedures compared with
GPs responsible for < 250 persons. Their odds of performing
a monofilament test were halved, OR 0.52. Further, screen-
ing procedures were reduced with 21% per 10 years increase
in the age of the GP (OR 0.79). GP gender, ethnicity or
number of days in clinical practice per week did not have a
significant effect on the recording of microvascular screening
procedures.
Table 1 Recorded microvascular screening procedures in the 8246
people with Type 2 diabetes in Norway included in the study
Microvascular screening procedures N (%)
Albuminuria test 2596 (31.5)
Monofilament test 2264 (27.5)
Eye examination 4946 (60.0)





*Tests for albuminuria, monofilament and/or eye examination.
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Practice characteristics associated with microvascular
screening procedures
Practices using reminders for people who did not attend
scheduled diabetes appointments or had established routines
for annual diabetes care review had almost double the odds of
recording two or more screening procedures (OR 1.92), in
particular the albuminuria test (OR 2.57) and the monofila-
ment test (1.75). Practices in which ancillary staff were
involved in screening procedures, had a 58% higher odds of
having recorded an eye examination (OR 1.58). Two counties
stood out regarding the recording of procedures with three to
four times higher odds than the reference county (Oslo).
Variation explained
Respectively, 22% and 37% of the variation in the proba-
bility of having two or more microvascular procedures
recorded was due to systematic differences between practices
and between GPs within practices. The heterogeneity was
larger for the albuminuria test and smaller for eye examina-
tion. After adjustment for population factors, the residual
cluster variation for the main outcome (two or more
procedures) was reduced by inclusion of GP and practice
factors, with the most substantial reduction occurring at
practice level. With regard to the separate procedures, we
were able to explain the least of the cluster variance for
the albuminuria test, whereas for eye examination we were
able to explain all of the systematic differences between
practices.
Discussion
This is the first study identifying several important associa-
tions with microvascular screening procedures and popula-
tion, GP and practice characteristics in routine clinical
practice for people with Type 2 diabetes. Performance of
screening procedures to detect microvascular complications
was low in our population, compared with reports from
Sweden, Scotland and the UK; albuminuria (73%–75%),
foot examination (80%–95%) and eye examination (87%–
90%) [10–12].
Characteristics of people with Type 2 diabetes
Consistent with a previous study [19], the youngest people
with diabetes had fewer screening procedures recorded. The
explanation might be that GPs think that these people are too
young to have developed complications. However, in Sweden
excess mortality has been shown in people with Type 2
diabetes and age < 55 years [20].
Because > 50% of the people with diabetes had adequate
glucose control in our study, GPs may consider microvascu-
lar screening to be unnecessary and downgrade screening
procedures in a busy working day. However, microvascular
complications are present also in newly diagnosed and well-
regulated people, with and without medication [21–23]. The
prevalence of albuminuria, neuropathy and retinopathy were
~ 10% each in newly diagnosed persons in the UK [21] and
the percentage of microvascular complications were similar
regardless of mean HbA1c levels at baseline; i.e. in the group
FIGURE 2 Venn diagram of 8246 people with Type 2 diabetes and a test for albuminuria, monofilament and/or eye examination.
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with mean HbA1c as low as 44 mmol/mol (6.2%) vs. the
group with mean HbA1c 58 mmol/mol (7.5%).
We found that people with diabetes at high risk of
developing complications, such as current smokers and
people with macrovascular complications were also less
likely to have microvascular screening procedures performed.
Their comorbidities might demand more attention during a
regular consultation, and consequently microvascular screen-
ing procedures may be omitted.
GP characteristics
A quarter of GPs used a structured diabetes form as part of
their routine practice, and they recorded microvascular
procedures more often than their counterparts, in particular
the monofilament test. The Noklus diabetes form probably
works as a reminder to the GPs to perform the recommended
processes of care. Additionally, most GPs that used the
electronic form in our study, also chose to send data to the
Norwegian Diabetes Registry for Adults, and consequently
got regular feedback on process indicators and results. A
systematic review of randomized controlled trials have
shown that feedback to GPs improves process outcomes
such as foot and eye examinations [14], although another
randomized study showed no effect on the performance of
eye examinations [24]. Using a simple web-based diabetes-
specific form in the Netherlands showed increased recordings
of process indicators compared with the GPs using only
electronic records [25].
GPs with a high number of people on their list had fewer
recordings of microvascular screening procedures, in particu-
lar the monofilament test, possibly because they find it time-
consuming.A recent report from theNorwegianDirectorate of
Health showed that GPs have an increasing number of
administrative tasks and long working days with an average
of 56 h per week including emergency service [26]. Our
Table 2 Characteristics of people with Type 2 diabetes included in the study
Characteristics
Missing observations
n (%) Median (10–90 percentiles) or percentage
N = 8246
Men – 55.0






Born in Western Europe/North America – 84.9
Education
Primary school – 36.6
High school/apprenticeship – 44.9
University – 18.4
Diabetes duration (years) – 7 (2–18)
Current smoker 1 524 (18) 22.1/18.0*
BMI (kg/m2) 4 434 (54) 29.1 (23.5–37.4)
Bariatric surgery 12 (0.1) 1.6/1.6*
Macrovascular complications† 21 (0.3) 27.3/27.3*
Coronary heart disease 9 (0.1) 22.2
Stroke 8 (0.1) 7.2
Peripheral arterial surgery 24 (0.3) 2.0
eGFR (ml min#1 1.73 m#2) 375 (4.5) 85.2 (52.0–105.7)
eGFR <45 ml min#1 1.73 m#2 6.4/6.1*
HbA1c (mmol/mol) 828 (10) 51 (40–68)
HbA1c (%) 6.8 (5.8-8.4)
HbA1c ≥ 64 mmol/mol (≥ 8.0%) 17.0/15.3*
SBP (mmHg) 984 (12) 135 (116–156)
BP >140/85 mmHg 35.6/31.4*
LDL (mmol/l) 1 242 (15) 2.6 (1.6-4.0)
LDL > 3.5 19.2/16.3*
Anti-hyperglycaemic therapy
Diet only - 30.9
Agents without insulin - 54.1
Agents combined with insulin - 15.0
Anti-hypertensives - 66.8
Lipid-lowering therapy - 56.1
Noklus diabetes form used‡ 18 (0.2) 24.2/24.1*
*Percentages of 8246 people were missing values are defined as ‘not registered with risk factor’.
†Composite variable of either coronary heart disease, stroke and/or peripheral arterial surgery.
‡If the Noklus diabetes form was ≥ 50% completed.
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observations also suggest that older GPs tend to omit perfor-
mance or documentation of microvascular screening proce-
dures. Comparable data on GP associations are sparse.
Practice characteristics
Practices with good routines for an annual diabetes care
review and a system for sending reminders to people who do
not meet for scheduled appointment were more likely to
perform microvascular screening procedures. This implies
that structure in diabetes care is important.
Previous studies have shown improved process indica-
tors when nurses assisted GPs [27,28]. In this study, we
did not find any significant associations with the number
of ancillary staff that could unburden the GPs workload.
Staff with diabetes competency or specific tasks related to
microvascular complication screening were positively
associated with the processes of care, but had no
significant impact in our multivariable analyses with the
exception of eye examination. However, in the UK,
Scotland and Sweden with high reported performance of
microvascular screening procedures in general practice,
nurses play an important role in diabetes care [10–12]. In
these countries, keys to success might have been the
support of political and financial systems, the county
council’s decision to support registration in a diabetes
Table 3 Characteristics of the general practitioners and practices included in the study
Characteristics Missing observations n (%) Median (10–90 percentiles) or percentage
GP (N = 281)
Men – 55.2
Age – 50 (34–64)
Born in Norway – 81.1
Medical education in Norway – 70.8
Years as a GP in Norway 11 (3.9) 18 (3–35)
≤ 5 18.1/19.9*
Specialist in general practice – 67.3








Clinical days per week > 3 – 81.5
No. of people on list – 1217 (792–1564)




User of Noklus diabetes form† – 26.0







Urban location – 80.5
No. of GPs per office – 3.0 (1.0–6.2)
No. of people with Type 2 diabetes – 120 (56–233)
No. of people on list per office – 4171 (1479–8103)
No. of people on list per full-time ancillary staff‡ – 1427 (805–1989)
Ancillary staff§
Any nurse employed – 42.9
Diabetes specialized nurse employed – 19.5
Ancillary staff attending diabetes course§ – 42.1
Duties related to microvascular complication screening¶ – 18.2
Diabetes competency‖ – 49.4
Routine annual diabetes review/reminders – 24.7
*Percentage after imputation.
†GP defined as a user of the form if used in ≥ 10 people with diabetes or > 50% of people with diabetes on the GP’s list.
‡Ancillary staff: nurses and medical secretaries.
§Attendance at a diabetes course within the last 3 years.
¶Foot examination, checking that albuminuria test or eye examination has been performed as recommended in national guidelines.
‖Diabetes competency: diabetes specialist nurse or attendance at a diabetes course within the last 3 years.
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registry, and the involvement of local nurses or team-
based district nurses [29,30].
Strengths and limitations
Our study presents real-life data from general practice. The
data quality is good because research nurses read all the
EHRs to verify electronically captured variables and col-
lected additional information from the records. The response
rate among GPs and practices were quite high, and all GPs
within a practice were included. Thus, our data set reflects
the quality of diabetes care in general practice. Further, we
had the possibility to adjust for characteristics of the people
with diabetes (including education and ethnicity) when
assessing GP and practice characteristics. We analysed a
comprehensive number of explanatory variables at three
different levels (population, GP and practice). We also
included the elderly > 80 years to give us a broad spectrum
of complication screening in general practice.
One of the strengths of our study is also our main
limitation; the use of EHR. Routinely collected data may be
inaccurate, and we have missing data. The missing data can
be caused by true missing variables, inconsistency between
care provided and care recorded, or selective performance of
processes. We excluded 705 people (7.9%) due to missing
data in one or more of the following variables: diabetes
duration (n = 562), ethnicity (n = 5), education (n = 168).
The people for whom diabetes duration had not been
recorded (6.3%) were older with a median age of 68 years,
had fewer screening procedures performed (two or more
screening procedures; 14.8%), and generally more incom-
plete health records. We suspect that at least some of these
people had newly diagnosed diabetes, thus would not have
been included in our analyses. Ethnicity and education were
gathered from Statistics Norway, thus this missingness was
unlikely to be related to diabetes care. We may have
underestimated the effect of current smoking, chronic kidney
disease, high HbA1c, hypertension and hyperlipidaemia as we
chose to categorize these variables and define missing values
to be ‘not registered with risk factor’. Finally, the observa-
tional design of our study prevents us from making claims
regarding causal relationships.
Table 4a Characteristics of people with Type 2 diabetes with odds ratios (OR) for having two or more microvascular screening procedures performed
Characteristics
Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
N = 8 246
Men 0.98 (0.88–1.09) 0.73 0.94 (0.83–1.05) 0.28
Age (years)
< 50 0.61 (0.50–0.73) <0.001 0.79 (0.65–0.98) 0.028
50–59 0.94 (0.81–1.10) 0.45 1.08 (0.92–1.27) 0.36
60–69 1 1
70–79 1.02 (0.88–1.17) 0.83 0.99 (0.85–1.15) 0.89
≥ 80 0.53 (0.44–0.63) <0.001 0.57 (0.46–0.69) <0.001
Born in Western Europe/North America 1.28 (1.08–1.53) 0.005 1.29 (1.07–1.57) 0.009
Education
Primary school 1 1
High school/apprenticeship 1.24 (1.10–1.40) <0.001 1.19 (1.04–1.35) 0.008
University 1.25 (1.07–1.45) 0.005 1.21 (1.03–1.42) 0.022
Diabetes duration per 5 years 1.21 (1.16–1.25) <0.001 1.14 (1.09–1.20) <0.001
Registered as current smoker* 0.74 (0.64–0.85) <0.001 0.68 (0.59–0.79) <0.001
Registered with bariatric surgery* 0.46 (0.29–0.73) 0.001 0.50 (0.31–0.82) 0.006
Registered with macrovascular complications*† 0.82 (0.73–0.93) 0.002 0.68 (0.59–0.78) <0.001
Registered with chronic kidney disease*‡ 0.75 (0.60–0.94) 0.011 0.78 (0.61–1.00) 0.050
Registered with high HbA1c*
§ 1.36 (1.17–1.57) <0.001 1.02 (0.86–1.20) 0.84
Registered with hypertension*¶ 1.20 (1.07–1.35) 0.002 1.20 (1.06–1.36) 0.003
Registered with hyperlipidaemia*‖ 0.82 (0.71–0.95) 0.007 0.99 (0.84–1.16) 0.87
Anti-hyperglycaemic therapy
Diet only 1 1
Agents without insulin 2.61 (2.28–2.99) <0.001 2.19 (1.89–2.53) <0.001
Agents combined with insulin 3.17 (2.65–3.78) <0.001 2.40 (1.94–2.95) <0.001
Anti-hypertensives 1.58 (1.40–1.78) <0.001 1.22 (1.07–1.40) 0.004
Lipid-lowering therapy 1.94 (1.73–2.17) <0.001 1.60 (1.41–1.83) <0.001
Multivariable results are adjusted for all characteristics listed in Tables 4a and 4b. All models include random intercepts for practices and for
general practitioners within practices.
*Missing observations are defined as ‘not registered with risk factor’.
†Composite variable of either coronary heart disease, stroke and/or peripheral arterial surgery.
‡eGFR <45 ml min#1 1.73 m#2.
§HbA1c ≥64 mmol/mol (≥8.0%).
¶Blood pressure >140/85 mmHg.
kLDL >3.5 mmol/l.
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GPs in two counties recorded more procedures than those
in other counties. This may be explained by the fact that two
opinion-leading diabetologists have for many years orga-
nized education sessions for GPs and ancillary staff in these
areas.
Implications
Our findings of the advantage of using a structured
electronic form as a reminder at the annual diabetes review
is, in our view, likely to be a general finding independent of
country. In particular, it will be of interest in countries
without a comprehensive diabetes register and where GPs
not are paid for performance. Further, we find poorer
performance of screening for microvascular complications in
the youngest, people with diabetes of short duration and
people with severe macrovascular complications. If repli-
cated in other studies, these findings would send a serious
signal to the diabetes community about suboptimal care in
these groups.
Although we have included a lot of variables related to
demographics and the health of people with diabetes, we
have no knowledge of other factors (psychological, motiva-
tional and practical) that may have reduced the likelihood of
procedures being performed. Furthermore, there was sub-
stantial residual heterogeneity between practices and
between GPs. A qualitative study comprising interviews with
people with diabetes, GPs and others involved in diabetes
care could provide further knowledge about why so many
people with diabetes are not being screened for microvascu-
lar complications.
Conclusion
There is considerable potential for improvement in compli-
cation screening in Norwegian general practice. We found
Table 4b Characteristics of general practitioners and practices with odds ratios (OR) for having two or more microvascular screening procedures
performed
Characteristic
Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
GP (N = 281)
Men 0.82 (0.63–1.07) 0.15 0.78 (0.58–1.04) 0.091
Age per 10 years 0.77 (0.68–0.88) <0.001 0.79 (0.66–0.93) 0.005
Born in Norway 1.23 (0.83–1.83) 0.31 1.25 (0.78–2.00) 0.35
Medical education in Norway 1.24 (0.90–1.70) 0.18 0.99 (0.67–1.44) 0.94
≤ 5 years as a GP in Norway* 0.82 (0.56–1.19) 0.29 1.15 (0.70–1.89) 0.58
Specialist in general practice 1.31 (0.95–1.80) 0.10 1.50 (1.00–2.25) 0.049
No. of people with Type 2 diabetes per GP
< 25 1 1
25–49 1.57 (1.07–2.32) 0.021 1.66 (1.09–2.53) 0.018
≥ 50 1.04 (0.67–1.60) 0.88 1.27 (0.76–2.12) 0.35
Clinical days per week > 3 1.09 (0.73–1.62) 0.67 0.71 (0.46–1.08) 0.11
Total no. of people on GP’s list per day worked each week
< 250 1 1
250–350 0.63 (0.42–0.96) 0.030 0.59 (0.39–0.90) 0.015
> 350 0.51 (0.31–0.84) 0.009 0.55 (0.32–0.94) 0.029




Akershus 1.35 (0.60–3.03) 0.47 1.25 (0.58–2.67) 0.57
Hordaland 1.79 (0.79–4.04) 0.16 1.78 (0.82–3.88) 0.15
Rogaland 3.59 (1.74–7.37) 0.001 2.71 (1.35–5.46) 0.005
Nordland 5.68 (2.89–11.17) <0.001 4.14 (1.87–9.16) <0.001
Urban location 0.51 (0.26–1.03) 0.062 1.51 (0.77–2.96) 0.24
No. of GPs per office 1.01 (0.87–1.18) 0.87 1.04 (0.92–1.18) 0.52
Ancillary staff†
Total no of people on list per full-time staff† 0.74 (0.56–0.97) 0.032 1.07 (0.82–1.41) 0.61
Duties related to microvascular complication screening‡ 2.63 (1.34–5.16) 0.005 1.15 (0.62–2.12) 0.66
Diabetes competency§ 2.35 (1.39–3.97) 0.001 1.09 (0.69–1.74) 0.71
Routines of annual diabetes review/reminders 2.19 (1.17–4.08) 0.014 1.92 (1.10–3.34) 0.021
Multivariable results are adjusted for all characteristics listed in Tables 4a and 4b. All models include random intercepts for practices and for
general practitioners within practices.
*Imputed for 11 GPs.
†Ancillary staff: nurses and medical secretaries.
‡Foot examination, or checking that albuminuria test and/or eye examination have been performed as recommended in national guidelines.
§Diabetes competency: diabetes specialist nurse or attendance at a diabetes course in the last 3 years.
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worse performance of microvascular screening procedures in
people not on anti-hyperglycaemic drugs and those with
diabetes of short duration despite guidelines recommending
microvascular screening at the time of diabetes diagnosis. In
addition, microvascular screening was low in people aged
< 50 years, smokers, those from minority ethnic groups,
people with a low level of education, and those with
macrovascular disease. The GPs’ use of a structural, elec-
tronic diabetes form was a strong positive predictor of
screening procedures, as were specialists in general practice,
and GP practices with established routines for an annual
diabetes care review. We suggest that diabetes care in general
practice can be improved by establishing good routines for
annual review and by making use of a structured electronic
form (or similar tool) mandatory.
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Table 5b Characteristics of general practitioners and practices with odds ratios (OR) for having a test for albuminuria, monofilament or eye
examination performed
Characteristic
Albuminuria Monofilament Eye examination¶
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
GP (N = 281)
Men 0.90 (0.62–1.30) 0.57 0.76 (0.56–1.03) 0.076 0.83 (0.68–1.01) 0.067
Age per 10 years 0.76 (0.61–0.94) 0.012 0.84 (0.71–1.00) 0.052 0.91 (0.82–1.02) 0.098
Born in Norway 1.01 (0.55–1.84) 0.98 1.40 (0.86–2.27) 0.17 1.10 (0.83–1.47) 0.51
Medical education in Norway 0.88 (0.54–1.43) 0.60 1.21 (0.81–1.81) 0.34 1.14 (0.89–1.45) 0.29
≤ 5 years as a GP in Norway* 1.34 (0.71–2.54) 0.91 1.22 (0.73–2.01) 0.45 0.98 (0.71–1.35) 0.89
Specialist in general practice 1.73 (1.01–2.96) 0.046 1.12 (0.74–1.69) 0.59 1.29 (1.00–1.66) 0.047
No. of people with Type 2 diabetes per GP
< 25 1 1 1
25–49 1.38 (0.81–2.35) 0.23 1.32 (0.86–2.04) 0.20 1.49 (1.13–1.98) 0.006
≥ 50 1.20 (0.63–2.29) 0.59 1.00 (0.59–1.68) 0.99 1.38 (1.00–1.92) 0.051
Clinical days per week > 3 0.89 (0.51–1.55) 0.67 0.74 (0.48–1.14) 0.17 0.79 (0.60–1.03) 0.085
Total no. people on GP’s list per clinical day
< 250 1 1 1
250–350 0.85 (0.48–1.49) 0.57 0.52 (0.34–0.80) 0.003 0.82 (0.64–1.06) 0.12
> 350 0.64 (0.32–1.31) 0.23 0.52 (0.31–0.89) 0.016 0.83 (0.61–1.14) 0.26
User of a structured diabetes form 1.45 (0.90–2.33) 0.13 4.51 (3.17–6.40) <0.001 1.38 (1.11–1.71) 0.004
Practice (N = 77)
County
Oslo 1 1 1
Akershus 1.18 (0.34–4.08) 0.80 1.65 (0.85–3.22) 0.14 0.82 (0.60–1.13) 0.23
Hordaland 0.73 (0.20–2.67) 0.64 2.27 (1.14–4.50) 0.019 2.43 (1.74–3.38) <0.001
Rogaland 3.43 (1.11–10.60) 0.032 3.28 (1.76–6.11) <0.001 1.78 (1.31–2.44) <0.001
Nordland 5.40 (1.47–19.89) 0.011 2.44 (1.22–4.91) 0.012 3.24 (2.27–4.63) <0.001
Urban location 1.74 (0.58–5.27) 0.32 1.06 (0.59–1.92) 0.84 0.92 (0.66–1.27) 0.61
No. of GPs per office 1.35 (1.08–1.67) 0.007 0.93 (0.84–1.04) 0.23 1.01 (0.95–1.06) 0.85
Ancillary staff†
Total no. of people on list
per full-time staff
1.05 (0.67–1.65) 0.82 1.15 (0.92–1.45) 0.23 1.01 (0.90–1.13) 0.84
Duties related to microvascular
complication screening‡
0.65 (0.24–1.78) 0.40 1.30 (0.77–2.21) 0.33 1.58 (1.20–2.08) 0.001
Diabetes competency§ 1.05 (0.49–2.27) 0.89 1.15 (0.77–1.72) 0.49 1.02 (0.83–1.25) 0.87
Routines of annual follow-up/reminders 2.57 (1.04–6.33) 0.040 1.75 (1.07–2.84) 0.025 1.13 (0.87–1.45) 0.36
Results from multivariable analyses include all characteristics listed in Tables 5a and 5b. The models also include random intercepts for
practices and for general practitioners within practices.
*Imputed value for 11 GPs.
†Ancillary staff: nurses and medical secretaries.
‡Foot examination, or checking that albuminuria test and/or eye examination have been performed as recommended in national guidelines.
§Diabetes competency: diabetes specialist nurse or attendance at a diabetes course within the last 3 years.
¶Multivariable analysis for eye examination is performed without random effects on practice level due to no unexplained variation.
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Aims To identify population, general practitioner, and practice characteristics associated with the achievement of
HbA1c, blood pressure and LDL cholesterol targets, and to describe variation in the achievement of risk factor control.
Methods We conducted a cross-sectional survey of 9342 people with type 2 diabetes, 281 general practitioners and 77
general practices in Norway. Missing values (7.4%) were imputed using multiple imputation by chained equations. We
used three-level logistic regression with the achievement of HbA1c, blood pressure and LDL cholesterol targets as
dependent variables, and factors related to population, general practitioners, and practices as independent variables.
Results Treatment targets were achieved for HbA1c in 64%, blood pressure in 50%, and LDL cholesterol in 52% of
people with type 2 diabetes, and 17% met all three targets. There was substantial heterogeneity in target achievement
among general practitioners and among practices; the estimated proportion of a GPs diabetes population at target was
55–73% (10–90 percentiles) for HbA1c, 36–63% for blood pressure, and 47–57% for LDL cholesterol targets. The
models explained 11%, 5% and 14%, respectively, of the total variation in the achievement of HbA1c, blood pressure
and LDL cholesterol targets. Use among general practitioners of a structured diabetes form was associated with 23%
higher odds of achieving the HbA1c target (odds ratio 1.23, 95% confidence interval (CI) 1.02–1.47) and 17% higher
odds of achieving the LDL cholesterol target (odds ratio 1.17, 95% CI 1.01–1.35).
Conclusions Clinical diabetes management is difficult, and few people meet all three risk factor control targets. The
proportion of people reaching target varied among general practitioners and practices. Several population, general
practitioner and practice characteristics only explained a small part of the total variation. The use of a structured
diabetes form is recommended.
Diabet. Med. 00, 1–11 (2019)
Introduction
People with type 2 diabetes have a doubled risk of death and
cardiovascular disease compared with the general population
[1]. The risk increases with each risk factor above target [2]. A
meta-analysis of randomized controlled trials (RCTs) has
shown a linear relationship between the reduction in HbA1c
andmajor cardiovascular events [3]. Another meta-analysis of
RCTs, showed that reaching blood pressure targets was
associated with decreased risk of diabetes-related mortality
[4]. Additionally, very low LDL cholesterol level was associ-
ated with reduced cardiovascular risk in people with type 2
diabetes [5]. It is therefore important for people with diabetes
to achieveHbA1c, blood pressure and LDL cholesterol targets.
Healthcare services in Norway are state-funded. Each
member of the population is listed with one specific general
practitioner (GP). GPs provide care for most individuals with
type 2 diabetes; however, they do not receive financial
incentives for the provision of a high quality of clinical care.
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In a recent study, we found major gaps between national
diabetes guidelines and the performance of screening to
detect microvascular complications, with significant hetero-
geneity among GPs within general practices [6]. The aim of
the present study was to examine how population charac-
teristics and available GP and practice characteristics were
associated with the achievement of HbA1c, blood pressure
and LDL cholesterol targets. In addition, we describe
variation in the achievement of targets.
Participants and methods
We used data from the ROSA 4 study, a cross-sectional
survey designed to assess the quality of diabetes care in
general practice in Norway in 2014. Verified and represen-
tative data from electronic health records in three of the four
health regions in Norway were collected and are described in
detail elsewhere [6].
In the present study we included 9342 adults (age ≥18
years) with type 2 diabetes (T90 in the International
Classification of Primary Care) who had their main follow-
up in their general practice, and who had a diabetes duration
of ≥6 months (Fig. 1). The included population was treated
by 281 GPs at 77 practices (73% and 77%, respectively, of
those invited to contribute data). Socio-economic variables
were obtained from Statistics Norway. Two questionnaires
were used to gather GP and practice characteristics (com-
pleted in 99% and 100% of cases).
The outcome variables were defined according to national
guidelines from 2009: HbA1c ≤53 mmol/mol (≤7.0%), blood
pressure ≤135/80 mmHg/≤140/85 mmHg (with/without anti-
hypertensive medication) and LDL cholesterol ≤1.8 mmol/l
with cardiovascular disease, or ≤2.5/≤3.5 mmol/l without
cardiovascular disease with/without lipid-lowering medica-
tion. We used the most recent target value between 1
October 2013 and 31 December 2014, although, if none was
available, the search period was extended backwards to 1
January 2012 (7.8% of HbA1c measurements and 19.1% of
LDL cholesterol measurements).
As explanatory variables, we included 12 diabetes popu-
lation characteristics (demographics, socio-economic status,
complications), 10 GP characteristics (demographics, spe-
ciality status and proxies for workload and routines), and
four practice characteristics (location, proxies for practice
size and routines); Table 1a,b.
Statistical analyses
Descriptive statistics are presented as medians with 10th and
90th percentiles for continuous variables, and counts and
percentages for categorical variables. Missing information
regarding individuals with diabetes (7.4%) was imputed
using multiple imputation by chained equations with predic-
tive mean matching, allowing for the multilevel structure of
the data [7]. In addition to the variables in the main models,
the imputations included the following as auxiliary variables:
weight; height; HbA1c; systolic blood pressure; diastolic
blood pressure; total cholesterol; HDL cholesterol; LDL
cholesterol; triglycerides; retinopathy; atrial fibrillation;
dialysis; and kidney transplantation. We produced 100
imputed datasets. Furthermore, number of years practising
in Norway was unknown for 11 GPs, and was single-
imputed based on the year of Norwegian authorization,
which was known for all GPs.
The associations between the outcomes and population,
GP and practice characteristics were analysed in three-level
logistic regression models including random intercepts for
GPs (level 2) and practices (level 3). Continuous explanatory
variables with severely non-linear effects on the log-odds
were analysed on a categorized scale. Variance inflation
factors were estimated to check for multicollinearity. We
report odds ratios (ORs) with 95% CIs for the achievement
of targets. Because of the large sample size and multiple
testing, corresponding chi-squared P values ≤0.01 for pop-
ulation characteristics and ≤0.05 for GP and practice
characteristics were considered statistically significant. The
models were fitted using adaptive Gaussian quadrature with
seven integration points. Results from the imputed datasets
were averaged by Rubin’s rules.
The proportion of variance explained by each full model
was estimated from the variance of the linear predictor for
the fixed portion of the model and from the estimated
random intercepts variances [8].
Heterogeneity in the achievement of targets among GPs
within practices was illustrated by means of ‘caterpillar’ plots
of empirical Bayes estimates of target achievement propor-
tions, obtained from three-level models without fixed effects
What’s new?
• Only one in five of those with type 2 diabetes in primary
care in Norway met all three targets for HbA1c, blood
pressure and LDL cholesterol.
• There was substantial heterogeneity in the achievement
of HbA1c, blood pressure and LDL cholesterol targets
among general practitioners and practices.
• The heterogeneity in risk factor control remained after
adjustment for case mix.
• Detailed analysis with 12 population-related, 10 gen-
eral practitioner-related and four practice-related fac-
tors explained <15% of the total variation in target
achievement.
• Most of the variation was at the population level.
• Young people, obese people and those with macrovas-
cular complications achieved targets less frequently.
• The use of a structured diabetes form is recommended.
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fitted to the original data, and with percentiles from the
empirical Bayes distributions. The total variation in the plots
reflects the sum of GP and practice random effects.
Furthermore, median ORs were calculated from the
estimated random intercept variances to quantify the cluster
heterogeneity [9], and are presented for GPs, practices, and
GPs and practices combined.
Finally, intraclass correlation coefficients were used to
estimate the proportion of outcome or residual variation
attributed to GPs, practices, and GPs within practices. The
CIs of intraclass correlation coefficients were estimated using
the logit transform as described in the STATA documentation
of estat icc, with standard errors estimated by the delta
method [10].
Supplementary analyses included linear regression analysis
with continuous outcomes and complete-case analysis.
The Venn diagram was made in PYTHON version 3.7 with
package matplotlib. Imputation was performed in R version
3.4 with packages mice and miceadds. For the regression
modelling, STATA version 15.1 was used with functions mi
estimate, melogit, mixed, and mimrgns.
Ethics
The study was approved by the Regional Health Commitee
in Norway (REK 2014/1374, REK Vest).
Results
The included population (n=9342; Fig. 1) was treated by 281
GPs at 77 practices (Table 1a,b). For the diabetes population
in which HbA1c, blood pressure and LDL cholesterol values
were available for all (n=7086), 64% achieved the HbA1c
target, 50% the blood pressure target and 52% the LDL
cholesterol target, and 17%met all three targets (Fig. 2). The
median (10th–90th percentile) values were as follows: HbA1c
51 (40–68) mmol/mol [6.8 (5.8–8.4%)]; systolic blood
pressure 134 (116–156) mmHg; diastolic blood pressure 80
(66–90) mmHg; and LDL cholesterol 2.6 (1.6–4.0).
Tables 2a and 2b show the estimated associations between
the achievement of targets and population, GP and practice
characteristics.
HbA1c
Compared with people in the age group 60–69 years, those
aged<50 yearswere less likely to achieve theHbA1c target (OR
0.60, 95% CI 0.51–0.71), while those aged ≥70 years were
more likely to achieve the target (Table 2a).Men, people born
outside Western Europe, and people with obesity had lower
odds of attaining the target. Long diabetes duration was also
negatively associated with the achievement of HbA1c target
(OR 0.65, 95%CI 0.62–0.67) per 5-year increase. People who
had undergone bariatric surgery had almost three times higher
odds of attaining the HbA1c target (OR 2.78, 95% CI 1.82–
4.25). People attending GPs who were regular users of a
structured diabetes form had 23%higher odds of attaining the
HbA1c target, (OR 1.23, 95% CI 1.02–1.47; Table 2b).
Blood pressure
People aged < 50 years were more likely to achieve blood
pressure targets (OR 1.49, 95% CI 1.26–1.77). Non-Western
ethnicity was positively associated with the achievement of
the blood pressure target, in particular South Asian ethnicity
(OR 1.99, 95% CI 1.61–2.46). Current smokers had higher
odds of achieving the blood pressure target (OR 1.20, 95%
CI 1.05–1.38). Obese people had reduced odds of achieving
the target (OR 0.76, 95% CI 0.66–0.87), while those with
BMI < 25 kg/m2 had increased odds of attaining blood
FIGURE 1 Flow chart of the exclusion process of participants in the ROSA 4 study (Rogaland-Oslo-Salten-Akershus-Hordaland study in 2014). GP,
general practitioner; LADA, latent autoimmune diabetes in adults; MODY, maturity-onset diabetes of the young.
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pressure target compared with those with BMI 25–29.9 kg/
m2 (OR 1.40, 95% CI 1.17–1.68). No GP or practice
characteristics were associated with the achievement of the
blood pressure target in our model.
LDL cholesterol
Men had higher odds of achieving the LDL cholesterol target
compared with women (OR 1.51, 95% CI 1.36–1.67). A
positive association with the achievement of LDL cholesterol
target was found in people of other ethnicity compared with
those of Western European/North American and South Asian
ethnicity (OR 1.39, 95% CI 1.16–1.66) and ex-smokers (OR
1.24, 95% CI 1.09–1.40). For each 5-year increase in
diabetes duration, the odds of reaching the LDL cholesterol
target increased by 18% (OR 1.18, 95% CI 1.13–1.23).
People with macrovascular complications were less likely to
achieve the LDL cholesterol target (OR 0.20, 95% CI 0.18–
0.22). GP users of a structured diabetes form had 17% higher
odds of getting the individuals with diabetes to the LDL
cholesterol target (OR 1.17, 95% CI 1.01–1.35).
Supplementary analyses
In supplementary analyses, models with continuous out-
comes mostly paralleled results from the logistic regression










Men - 5110 (55)
Age - 66 (48–82)
< 50 years 1194 (13)
50–59 years 1884 (20)
60–69 years 2766 (30)
70–79 years 2231 (24)





South Asian† 726 (7.8)
Other 843 (9.0)
Education 181 (1.9)
Primary school - 3373 (37)
High school/apprenticeship - 4102 (45)
University - 1686 (18)
Diabetes duration (years) 562 (6.0) 7 (1-18)
Smoking status 1933 (21)
Never smoked 3315 (45)
Ex-smoker 2413 (33)
Current smoker 1681 (23)
BMI 5153 (55) 29 (24-38)
< 25 kg/m2 772 (18)
25–29.9 kg/m2 1558 (37)
≥ 30 kg/m2 1859 (44)
Bariatric surgery 12 (0.1) 143 (1.5)
Macrovascular complications‡ 22 (0.2) 2513 (27)
Foot ulcer 13 (0.1) 251 (2.7)
Lower limb amputation 8 (0.1) 55 (0.6)
Estimated GFR 452 (4.8)
> 60 ml/min/1.73 m2 7489 (84)
45–59 ml/min/1.73 m2 839 (9.4)
30–44 ml/min/1.73 m2 400 (4.5)
< 30 ml/min/1.73 m2 162 (1.8)
*Born in Western Europe or North America. †Born in
Bangladesh, India, Pakistan or Sri-Lanka. ‡Composite variable
of either coronary heart disease, stroke and/or peripheral
arterial surgery.
Table 1b Characteristics of 281 general practitioners and 77 practices









GPs (n = 281)
Men - 155 (55)
Age - 50 (34–64)
< 40 years 65 (23)
40–49 years 75 (27)
50–59 years 65 (23)
≥ 60 years 76 (27)




Years as a GP in Norway 11 (3.9) 18 (3–35)
≤ 5 years as a
GP in Norway
49 (18)/(20)*
Specialist in general practice - 189 (67)
Number of people with type
2 diabetes on list
- 34 (14–60)
< 25 66 (24)
25–49 132 (47)
≥ 50 83 (30)
Clinical days per week > 3 - 229 (82)
Total number of people
on GP’s list per day
worked each week
- 296 (218–392)
< 225 73 (26)
225–300 81 (29)
301–375 94 (34)
> 375 33 (12)
User of a structured
diabetes form†
- 73 (26)
Practice (n = 77)
County
Oslo - 12 (16)
Akershus - 10 (13)
Hordaland - 10 (13)
Rogaland - 19 (25)
Nordland - 26 (34)
Number of GPs per office - 3 (1-6)
Number of people on list
per full-time ancillary staff
- 1427 (805–1989)
< 1250 24 (31)
1250–1750 35 (46)
> 1750 18 (23)




*Percentage after imputation. †GP defined as a user of the form
if used in ≥10 people with diabetes or more than 50% of the
people with diabetes on the GP’s list.
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analysis (Table S1). Predicted probabilities are presented in
Table S2. In the complete-case analyses (n=3530 for HbA1c
target, n=3462 for blood pressure target, n=3308 for LDL
cholesterol target; data not shown), there were only minor
changes in the effect estimates, that is, the effect of using a
diabetes form was slightly reduced, in particular for achiev-
ing the LDL cholesterol target which was non-significant. In
analyses excluding people aged ≥80 years, the results were
similar to the full model (data not shown).
Variation
The fixed effects of the full model explained 11% of the
variation in achievement of HbA1c target, whereas fixed and
random effects together explained 16% of the variation. The
corresponding results for the blood pressure target were 5%
and 11%, and for LDL cholesterol target 14% and 16%.
We found statistically significant variation among GPs and
among practices for all targets. Figures 3a–c show the varia-
tion in predicted proportions of target achievement for the
individual GPs within practices. For the HbA1c target, 80% of
GPs within practices were predicted to lie between 55% and
73% target achievement. For blood pressure target the
variation was bigger, with the 10th to 90th percentile predicted
target achievement range being 36% to63%;whereas for LDL
cholesterol the corresponding range was 47% to 57%.
Similarly, individuals treated by a well-performing GP
within a well-performing practice had a median 50% higher
odds of HbA1c target achievement than those treated by a GP
with poorer performance at a practice with poorer results
(median OR 1.50, 95% CI 1.36–1.73). For blood pressure
and LDL cholesterol targets the corresponding median ORs
were 1.61 (95% CI 1.45–1.85) and 1.28 (95% CI 1.19–
1.53), respectively. Apart from for LDL cholesterol, the
heterogeneity was distributed relatively evenly between GPs
and practices, and changed only slightly when adjusting for
population, GP and practice factors (Table S3).
By contrast, the residual variation in target achievement
was mostly between individuals. The unconditional com-
bined intraclass correlation coefficients for GPs within
practices were 5.3 (95% CI 3.7–7.5)%, 7.0 (95% CI 5.2–
9.6)% and 2.3 (95% CI 1.4–3.8)% for the HbA1c, blood
pressure and LDL cholesterol targets, respectively, and the
conditional intraclass correlation coefficients from adjusted
models were similar.
Discussion
Clinical management of diabetes is difficult, and only one in
five achieved all three targets for HbA1c, blood pressure and
LDL cholesterol. This is one of few studies with several
explanatory variables on three levels that aim to explore
variation in, and factors associated with, the achievement of
targets [11]. Young people (age <50 years), people with
obesity and those with long diabetes duration were less likely
to achieve the HbA1c target, while people with macrovascu-
lar disease had lower odds of achieving the LDL cholesterol
target. We observed that a small positive effect on the
achievement of HbA1c and LDL cholesterol targets was
related to GP usage of a structured diabetes form. After
adjusting for case mix, there was a moderate residual
heterogeneity in target achievement among GPs within
FIGURE 2 Proportion of people with type 2 diabetes achieving HbA1c, blood pressure and LDL cholesterol targets where measurements were
available for all (n=7086). HbA1c target: ≤53 mmol/mol (≤7.0%); blood pressure target: ≤135/80 mmHg/≤140/85 mmHg (with/without anti-
hypertensive medication); LDL cholesterol target: ≤1.8 mmol/l with cardiovascular disease, or without cardiovascular disease, ≤2.5/≤3.5 mmol/l
with/without lipid-lowering medication.
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practices, which could only partly be explained by the
studied GP and practice characteristics.
We observed that younger people had worse glycaemic
control than people aged >60 years. This finding has also
been reported in other countries [12,13]. A large observa-
tional study in Sweden showed that people with type 2
diabetes aged <55 years had the highest increase in risk of
cardiovascular disease and death compared with similarly
aged controls [2]. HbA1c level outside target range was also a
strong predictor for all cardiovascular outcomes [2].
People with macrovascular complications had low odds of
attaining the LDL cholesterol target. In the randomized
IMPROVE-IT trial, very low LDL cholesterol levels in people
with type 2 diabetes and acute coronary syndrome reduced
the incidence of cardiovascular outcomes after 7 years
follow-up [5]. Thus, intensification of lipid-lowering therapy
among individuals with a history of macrovascular disease
should be prioritized.
In the present study, obese people were less likely to achieve
HbA1c and blood pressure targets. In the ADDITION-Cam-
bridge trial, weight loss in the first year following a diabetes
diagnosis was associated with reduced incidence of cardio-
vascular disease [14]. Initial weight loss in people with newly
diagnosed type 2 diabetes should therefore be encouraged.
We did not measure adherence to medical or lifestyle
advice, motivation for lifestyle changes, individual prefer-
ences or hypoglycaemic episodes. Poor medication adherence
has been identified as a major cause for the observed efficacy
gap in HbA1c reduction between RCTs and the real world
[15]. A Danish study showed that low frequency of self-
monitoring of blood glucose, perceived low treatment
efficacy, low adherence, and low primary care utilization
were associated with high levels of HbA1c and LDL choles-
terol [16]. In the multinational IntroDia study approximately
one in five people with type 2 diabetes negotiated with their
physician to delay additional medication after initial
Table 2a Characteristics of people with type 2 diabetes with adjusted* odds ratios for the achievement of HbA1c, blood pressure or LDL cholesterol target
Characteristics
HbA1c target
† Blood pressure target‡ LDL cholesterol target§
OR (95% CI) P OR (95% CI) P OR (95% CI) P
N = 9342
Men 0.87 (0.79, 0.96) 0.005 0.96 (0.87, 1.06) 0.43 1.51 (1.36, 1.67) <0.001
Age
< 50 years 0.60 (0.51, 0.71) <0.001 1.49 (1.26, 1.77) <0.001 1.11 (0.94, 1.31) 0.23
50–59 years 0.72 (0.63, 0.82) <0.001 1.15 (1.01, 1.32) 0.038 0.95 (0.83, 1.09) 0.47
60–69 years 1 1 1
70–79 years 1.36 (1.19, 1.56) <0.001 0.84 (0.74, 0.96) 0.009 1.18 (1.03, 1.34) 0.015
≥ 80 years 1.26 (1.06, 1.51) 0.010 0.69 (0.58, 0.82) <0.001 1.21 (1.01, 1.45) 0.04
Ethnicity
Western European/North American¶ 1 1 1
South Asian** 0.66 (0.54, 0.80) <0.001 1.99 (1.61, 2.46) <0.001 1.28 (1.04, 1.56) 0.019
Other 0.67 (0.56, 0.79) <0.001 1.48 (1.24, 1.78) <0.001 1.39 (1.16, 1.66) <0.001
Education
Primary school 1 1 1
High school/apprenticeship 1.06 (0.95, 1.18) 0.30 1.07 (0.96, 1.19) 0.20 1.06 (0.95, 1.18) 0.28
University 1.02 (0.89, 1.17) 0.79 1.02 (0.89, 1.18) 0.74 1.01 (0.88, 1.17) 0.85
Diabetes duration per 5 years 0.65 (0.62, 0.67) <0.001 1.00 (0.97, 1.04) 0.85 1.18 (1.13, 1.23) <0.001
Smoking status
Never smoked 1 1 1
Ex-smoker 1.07 (0.95, 1.21) 0.29 1.10 (0.98, 1.24) 0.12 1.24 (1.09, 1.40) 0.001
Current smoker 0.90 (0.79, 1.04) 0.15 1.20 (1.05, 1.38) 0.009 1.00 (0.86, 1.15) 0.96
BMI
< 25 kg/m2 1.20 (1.00, 1.45) 0.056 1.40 (1.17, 1.68) <0.001 1.08 (0.82, 1.43) 0.58
25–29.9 kg/m2 1 1 1
≥ 30 kg/m2 0.78 (0.67, 0.91) 0.002 0.76 (0.66, 0.87) <0.001 0.94 (0.76, 1.17) 0.57
Bariatric surgery 2.78 (1.82, 4.25) <0.001 1.36 (0.92, 2.00) 0.13 1.61 (1.08, 2.38) 0.018
Macrovascular complications†† 0.92 (0.82, 1.03) 0.15 1.11 (0.99, 1.24) 0.075 0.20 (0.18, 0.22) <0.001
Foot ulcer 0.80 (0.59, 1.09) 0.16 0.74 (0.54, 1.03) 0.071 1.07 (0.76, 1.50) 0.71
Lower limb amputation 0.58 (0.30, 1.15) 0.12 1.34 (0.67, 2.70) 0.41 0.96 (0.47, 1.95) 0.90
Estimated GFR
> 60 ml/min/1.73 m2 1 1 1
45–59 ml/min/1.73 m2 0.95 (0.80, 1.14) 0.59 0.92 (0.78, 1.09) 0.35 1.08 (0.90, 1.28) 0.40
30–44 ml/min/1.73 m2 0.78 (0.61, 0.98) 0.04 1.05 (0.83, 1.33) 0.66 0.87 (0.68, 1.12) 0.29
<30 ml/min/1.73 m2 0.86 (0.60, 1.24) 0.43 0.99 (0.69, 1.41) 0.94 1.13 (0.76, 1.67) 0.55
GP, general practitioner.
*Adjusted for all population, GP and practice characteristics included in Tables 2a and 2b. †HbA1c ≤53 mmol/mol (≤7.0%).
‡Blood pressure
≤135/80 mmHg/≤140/85 mmHg (with/without antihypertensive medication). §LDL cholesterol ≤1.8 mmol/l with cardiovascular disease, or
without cardiovascular disease; ≤2.5/≤3.5mmol/l with/without lipid-lowering medication. ¶Born inWestern Europe or North America. **Born
in Bangladesh, India, Pakistan or Sri-Lanka. ††Composite variable of either coronary heart disease, stroke and/or peripheral arterial surgery.
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monotherapy, two-thirds successfully [17]. A justifiable
source of variation is individualized targets due to multi-
morbidity and short life expectancy, individual preferences
and resources. Personalized treatment leads to a higher
achievement of risk factor control [18] and is encouraged in
international guidelines [19].
People whose GPs used a structured diabetes form were
more likely to achieve the HbA1c and LDL cholesterol targets.
GP usage of the form was also associated with higher odds of
performingmicrovascular screening procedures (OR2.65) [6].
Prescribing and intensifying medication is the GP’s main
tool to influence risk factor control. Due to the cross-
sectional design of the present study, we were not able to
assess GP prescription patterns. GPs’ choices regarding
prescriptions are best studied with longitudinal data. A
review of GPs’ views on barriers to prescribing insulin found
that time constraints, insulin skills, collaboration between
primary and secondary care and perception of barriers for
the person with diabetes influenced the initiation of insulin
[20]. Another review found that delays in initiating or
intensifying anti-hyperglycaemic therapy often exceeded 3
years [21]. Clinical inertia can be related to individuals with
diabetes, their provider and healthcare system [22].
None of the included practice characteristics were signif-
icantly associated with the achievement of targets in the
present study; however, with wide CIs we cannot exclude the
possibility of some effects. A meta-analysis of RCTs showed
no change in HbA1c where nurse prescribers supplemented a




† Blood pressure target‡ LDL cholesterol target§
OR (95% CI) P OR (95% CI) P OR (95% CI) P
GP (N=281)
Men 1.02 (0.88, 1.19) 0.78 0.91 (0.77, 1.07) 0.23 0.98 (0.85, 1.12) 0.73
Age
< 40 years 1 1 1
40–49 years 1.19 (0.93, 1.51) 0.16 1.15 (0.89, 1.48) 0.29 1.05 (0.86, 1.29) 0.61
50–59 years 0.96 (0.73, 1.25) 0.74 1.18 (0.89, 1.56) 0.24 1.13 (0.90, 1.42) 0.28
≥ 60 years 1.03 (0.79, 1.35) 0.81 0.98 (0.74, 1.30) 0.89 1.04 (0.83, 1.31) 0.72
Born outside Norway 1.08 (0.85, 1.36) 0.53 1.03 (0.80, 1.31) 0.84 0.96 (0.79, 1.17) 0.69
Medical education outside Norway 0.96 (0.79, 1.16) 0.64 1.05 (0.85, 1.28) 0.67 0.96 (0.81, 1.13) 0.64
≤ 5 years as a GP in Norway¶ 1.11 (0.85, 1.45) 0.45 1.05 (0.79, 1.39) 0.76 0.87 (0.69, 1.09) 0.22
Specialist in general practice 1.15 (0.94, 1.41) 0.16 1.04 (0.84, 1.29) 0.70 0.91 (0.77, 1.08) 0.30
Clinical days per week > 3 0.95 (0.76, 1.20) 0.69 0.98 (0.77, 1.24) 0.85 1.06 (0.87, 1.29) 0.57
Number of people with type
2 diabetes per GP
< 25 1 1 1
25–49 1.01 (0.79, 1.28) 0.96 1.14 (0.89, 1.46) 0.30 1.08 (0.88, 1.33) 0.47
≥ 50 0.92 (0.70, 1.22) 0.57 1.16 (0.87, 1.55) 0.32 1.04 (0.82, 1.32) 0.73
Total no. of persons on
GPs list per day worked each week
< 225 1.13 (0.90, 1.42) 0.30 0.89 (0.70, 1.12) 0.32 1.10 (0.92, 1.32) 0.29
225–300 1 1 1
301–375 0.94 (0.79, 1.12) 0.51 0.94 (0.78, 1.13) 0.53 1.02 (0.88, 1.19) 0.77
> 375 1.10 (0.84, 1.43) 0.50 0.82 (0.62, 1.09) 0.17 0.94 (0.75, 1.18) 0.57
User of a structured diabetes form** 1.23 (1.02, 1.47) 0.03 1.09 (0.90, 1.32) 0.40 1.17 (1.01, 1.35) 0.03
Practice (N=77)
County
Oslo 1 1 1
Akershus 1.08 (0.75, 1.56) 0.68 1.10 (0.76, 1.59) 0.62 0.97 (0.77, 1.22) 0.79
Hordaland 1.09 (0.76, 1.56) 0.65 0.93 (0.64, 1.34) 0.69 0.78 (0.62, 0.98) 0.03
Nordland 0.87 (0.61, 1.23) 0.43 0.71 (0.50, 1.01) 0.054 0.75 (0.60, 0.94) 0.013
Rogaland 1.02 (0.74, 1.41) 0.92 1.05 (0.75, 1.46) 0.77 0.78 (0.63, 0.97) 0.02
Number of GPs per office 1.02 (0.96, 1.08) 0.55 0.97 (0.91, 1.03) 0.29 1.01 (0.97, 1.05) 0.59
Number of people on list per
full-time ancillary staff††
< 1250 1 1 1
1250–1750 1.18 (0.86, 1.62) 0.30 0.79 (0.57, 1.09) 0.16 0.90 (0.74, 1.10) 0.31
> 1750 1.09 (0.74, 1.62) 0.66 0.80 (0.54, 1.20) 0.29 0.95 (0.74, 1.21) 0.67
Routines of annual follow-up/reminders 0.97 (0.76, 1.22) 0.78 0.95 (0.75, 1.20) 0.66 1.07 (0.93, 1.24) 0.33
GP, general practitioner.
*Adjusted forall population,GPandpractice characteristics included inTables2aand2b. †HbA1c≤53mmol/mol (≤7.0%).
‡Bloodpressure≤135/
80 mmHg/≤140/85 mmHg (with/without antihypertensive medication). §LDL cholesterol ≤1.8 mmol/l with cardiovascular disease, or without
cardiovascular disease;≤2.5/≤3.5mmol/lwith/without lipid-loweringmedication. ¶Imputed for 11GPs. **GPdefined as auser of the form if used
in ≥10 people with diabetes or more than 50% of the people with diabetes on the GP’s list. ††Ancillary staff: nurses and medical secretaries.
ª 2019 The Authors.
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team, however, in people served by nurse prescribers
glycaemic control was non-inferior to people served by GPs
[23]. In other studies significant and positive associations
with diabetes specialized nurses, diabetes team, group
education and reduced HbA1c have been reported [24,25].
Unfortunately, diabetes specialized nurses are rare in Nor-
wegian general practice. Other studies have shown that
multifaceted interventions on multidisciplinary teams
resulted in better glycaemic control [26], and benchmarking
in the multinational OPTIMISE study increased the number
of people achieving blood pressure and LDL cholesterol
targets [27].
We describe statistically significant variation in the pro-
portion of people achieving targets among GPs within
practices, and correspondingly, moderately sized median
ORs and intraclass correlation coefficients. An intraclass
correlation coefficient of 3% for clustering at practices was
found for the combined achievement of HbA1c, blood
pressure and cholesterol in a large study from general
practice in UK [28]. Three-level studies on treatment targets
in general practice are rare; however, one study showed that
> 95% of the variance in HbA1c outcomes was at the
population level, whereas only 2.8% and 1.9% was at the
GP and practice level [11]. The variance pattern did not
change when five population and three GP characteristics
were added to the model. Their model explained 12% of the
total variation; it was very similar to the presented full model
for HbA1c which explained 11% of the variation in our data.
In two-level studies, GP or practice variables explained only
4.9%, 5.7% and 2.1% of the total variation in the
achievement of HbA1c, blood pressure and cholesterol
targets [29,30].
The main strength of the present study was its large sample
of people with diabetes, and inclusion of a substantial
number of GPs within a variety of practice types. This
enabled us to describe variation in outcomes at three levels.
People with diabetes are registered with one specific GP
within one practice and we have assessed several important
variables that are not routinely collected and available in
other studies. The participants are considered to be repre-
sentative of the diabetes population in Norway.
Nevertheless, owing to the cross-sectional design, we were
unable to draw conclusions regarding causality. Further-
more, analyses are based on a single measurement of each
outcome, which may not be representative of the ‘true’ level
of a person’s HbA1c, blood pressure, or LDL cholesterol.
This is mostly a concern with regard to HbA1c and for
shorter disease durations, in which there can be substantial
fluctuations.
The included variables explain only a small part of the
total variation; however, a large proportion of unexplained
variation has also been found in several other prediction
models [11,29,30]. We lack information on population
characteristics regarding diet, physical activity, individual
barriers, adherence to therapy, and comorbidities. We would
also have liked to assess the effect of good GP communica-
tors and dedicated prescribers, GPs with a special interest in
diabetes, and GPs’ barriers to treatment.
The use of electronic health records as a data source can
result in a considerable amount of missing data; however, in
the present study all 9342 medical journals were manually
scrutinized by research nurses who supplemented the
database with information not captured electronically.
Missing data were imputed, including missing measurements
for HbA1c, blood pressure and LDL cholesterol values, which
may protect against bias from data missing not at random
[7].
In summary, the clinical management of diabetes is
challenging, and only one in five people with diabetes
met all three targets for HbA1c, blood pressure and LDL
cholesterol. The largest variation in the achievement of
targets was at the population level. However, the proportion
of people reaching target varied among GPs and practices,
also after adjusting for case mix. Most of the variation in risk
factor control was not explained by the 12 population, 10 GP
and four practice characteristics included in the present
study. Despite this unexplained variation, the clinical impli-
cations of the study are that more attention should be
focused on young people, people with obesity and those with
macrovascular disease, and the use of a structured diabetes
form is recommended.
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